Tenet Healthcare (THC) 10-Q 28 Apr 23 2023 Q1 Quarterly report Financial data

Cover Page

Cover Page - shares	3 Months Ended
	Mar. 31, 2023	Apr. 21, 2023
Document Information [Line Items]
Document Type	10-Q
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	1-7293
Entity Registrant Name	TENET HEALTHCARE CORP
Entity Incorporation, State or Country Code	NV
Entity Tax Identification Number	95-2557091
Entity Address, Address Line One	14201 Dallas Parkway
Entity Address, City or Town	Dallas
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	75254
City Area Code	469
Local Phone Number	893-2200
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		101,935,159
Entity Central Index Key	0000070318
Current Fiscal Year End Date	--12-31
Document Period End Date	Mar. 31, 2023
Document Fiscal Year Focus	2023
Document Fiscal Period Focus	Q1
Amendment Flag	false
Common stock, $0.05 par value | New York Stock Exchange
Document Information [Line Items]
Title of 12(b) Security	Common stock, $0.05 par value
Trading Symbol	THC
Security Exchange Name	NYSE
6.875% Senior Notes due 2031 | New York Stock Exchange
Document Information [Line Items]
Title of 12(b) Security	6.875% Senior Notes due 2031
Trading Symbol	THC31
Security Exchange Name	NYSE

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 766	$ 858
Accounts receivable	2,883	2,943
Inventories of supplies, at cost	407	405
Assets held for sale	142	0
Other current assets	1,671	1,775
Total current assets	5,869	5,981
Investments and other assets	3,175	3,147
Deferred income taxes	14	19
Property and equipment, at cost, less accumulated depreciation and amortization ($6,225 at March 31, 2023 and $6,201 at December 31, 2022)	6,319	6,462
Goodwill	10,258	10,123
Other intangible assets, at cost, less accumulated amortization ($1,429 at March 31, 2023 and $1,428 at December 31, 2022)	1,432	1,424
Total assets	27,067	27,156
Current liabilities:
Current portion of long-term debt	148	145
Accounts payable	1,192	1,504
Accrued compensation and benefits	602	778
Professional and general liability reserves	256	255
Accrued interest payable	248	213
Liabilities held for sale	23	0
Contract liabilities	76	110
Other current liabilities	1,674	1,471
Total current liabilities	4,219	4,476
Long-term debt, net of current portion	14,935	14,934
Professional and general liability reserves	810	790
Defined benefit plan obligations	330	331
Deferred income taxes	220	217
Other long-term liabilities	1,748	1,800
Total liabilities	22,262	22,548
Commitments and contingencies
Redeemable noncontrolling interests in equity of consolidated subsidiaries	2,225	2,149
Shareholders’ equity:
Common stock, $0.05 par value; authorized 262,500,000 shares; 157,032,313 shares issued at March 31, 2023 and 156,462,456 shares issued at December 31, 2022	8	8
Additional paid-in capital	4,774	4,778
Accumulated other comprehensive loss	(179)	(181)
Accumulated deficit	(660)	(803)
Common stock in treasury, at cost, 55,120,211 shares at March 31, 2023 and 54,215,871 shares at December 31, 2022	(2,710)	(2,660)
Total shareholders’ equity	1,233	1,142
Noncontrolling interests	1,347	1,317
Total equity	2,580	2,459
Total liabilities and equity	$ 27,067	$ 27,156

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Statement of Financial Position [Abstract]
Property and equipment, accumulated depreciation and amortization	$ 6,225	$ 6,201
Accumulated amortization	$ 1,429	$ 1,428
Common stock, par value (in dollars per share)	$ 0.05	$ 0.05
Common stock, authorized shares (in shares)	262,500,000	262,500,000
Common stock, shares issued (in shares)	157,032,313	156,462,456
Common stock in treasury (in shares)	55,120,211	54,215,871

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Statement [Abstract]
Net operating revenues	$ 5,021	$ 4,745
Grant income	3	6
Equity in earnings of unconsolidated affiliates	50	46
Operating expenses:
Salaries, wages and benefits	2,258	2,182
Supplies	891	785
Other operating expenses, net	1,093	942
Depreciation and amortization	217	203
Impairment and restructuring charges, and acquisition-related costs	21	16
Litigation and investigation costs	4	20
Net losses (gains) on sales, consolidation and deconsolidation of facilities	(13)	1
Operating income	603	648
Interest expense	(221)	(227)
Other non-operating expense, net	(2)	0
Loss from early extinguishment of debt	0	(43)
Income from continuing operations, before income taxes	380	378
Income tax expense	(84)	(99)
Income from continuing operations, before discontinued operations	296	279
Discontinued operations:
Income from operations	0	1
Income from discontinued operations	0	1
Net income	296	280
Less: Net income available to noncontrolling interests	153	140
Net income available to Tenet Healthcare Corporation common shareholders	143	140
Amounts available to Tenet Healthcare Corporation common shareholders
Income from continuing operations, net of tax	143	139
Income from discontinued operations, net of tax	0	1
Net income available to Tenet Healthcare Corporation common shareholders	$ 143	$ 140
Basic
Continuing operations (in dollars per share)	$ 1.40	$ 1.29
Discontinued operations (in dollars per share)	0	0.01
Total earnings (loss) per share, basic (in dollars per share)	1.40	1.30
Diluted
Continuing operations (in dollars per share)	1.32	1.27
Discontinued operations (in dollars per share)	0	0.01
Total earnings (loss) per share, diluted (in dollars per share)	$ 1.32	$ 1.28
Weighted average shares and dilutive securities outstanding (in thousands):
Basic (in shares)	102,289	107,483
Diluted (in shares)	106,006	112,020

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF OTHER COMPREHENSIVE INCOME - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Comprehensive Income [Abstract]
Net income	$ 296	$ 280
Other comprehensive income:
Amortization of net actuarial loss included in other non-operating expense, net	2	2
Unrealized losses on debt securities held as available-for-sale	0	(2)
Other comprehensive income before income taxes	2	0
Income tax benefit related to items of other comprehensive income	0	0
Total other comprehensive income, net of tax	2	0
Comprehensive net income	298	280
Less: Comprehensive income available to noncontrolling interests	153	140
Comprehensive income available to Tenet Healthcare Corporation common shareholders	$ 145	$ 140

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Statement of Cash Flows [Abstract]
Net income	$ 296	$ 280
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation and amortization	217	203
Deferred income tax expense	8	63
Stock-based compensation expense	14	16
Impairment and restructuring charges, and acquisition-related costs	21	16
Litigation and investigation costs	4	20
Net losses (gains) on sales, consolidation and deconsolidation of facilities	(13)	1
Loss from early extinguishment of debt	0	43
Equity in earnings of unconsolidated affiliates, net of distributions received	11	21
Amortization of debt discount and debt issuance costs	9	8
Pre-tax income from discontinued operations	0	(1)
Net gains from the sale of investments and long-lived assets	(14)	(68)
Other items, net	(2)	4
Changes in cash from operating assets and liabilities:
Accounts receivable	35	(151)
Inventories and other current assets	50	181
Income taxes	76	29
Accounts payable, accrued expenses, contract liabilities and other current liabilities	(230)	(360)
Other long-term liabilities	(9)	(21)
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements	(24)	(56)
Net cash provided by operating activities	449	228
Cash flows from investing activities:
Purchases of property and equipment	(235)	(155)
Purchases of businesses or joint venture interests, net of cash acquired	(48)	(40)
Proceeds from sales of facilities and other assets	13	148
Proceeds from sales of marketable securities, long-term investments and other assets	9	6
Purchases of marketable securities and equity investments	(18)	(19)
Other items, net	(7)	0
Net cash used in investing activities	(286)	(60)
Cash flows from financing activities:
Repayments of borrowings	(45)	(879)
Proceeds from borrowings	12	2
Repurchases of common stock	(50)	0
Debt issuance costs	0	(3)
Distributions paid to noncontrolling interests	(134)	(135)
Proceeds from the sale of noncontrolling interests	25	4
Purchases of noncontrolling interests	(41)	(14)
Other items, net	(22)	(102)
Net cash used in financing activities	(255)	(1,127)
Net decrease in cash and cash equivalents	(92)	(959)
Cash and cash equivalents at beginning of period	858	2,364
Cash and cash equivalents at end of period	766	1,405
Supplemental disclosures:
Interest paid, net of capitalized interest	(177)	(166)
Income tax payments, net	$ 0	$ (8)

BASIS OF PRESENTATION

BASIS OF PRESENTATION	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
BASIS OF PRESENTATION	BASIS OF PRESENTATION Description of Business and Basis of Presentation Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as “Tenet,” “we” or “us”) is a diversified healthcare services company headquartered in Dallas, Texas. Our care delivery network includes our subsidiary USPI Holding Company, Inc. (“USPI”), which had indirect ownership interests in 445 ambulatory surgery centers and 24 surgical hospitals at March 31, 2023. We hold noncontrolling interests in 156 of these facilities, which are recorded using the equity method of accounting. We also operated 61 acute care and specialty hospitals, 109 other outpatient facilities, a network of employed physicians and a Global Business Center (“GBC”) in Manila, Philippines at March 31, 2023. In addition, we operate Conifer Health Solutions, LLC, in which we own an interest of approximately 76%, through our Conifer Holdings, Inc. subsidiary (“Conifer”). Effective June 30, 2022, we purchased all of the shares previously held by Baylor University Medical Center (“Baylor”) in USPI for $406 million, which increased our ownership interest in USPI’s voting shares from 95% to 100%. See Note 13 for additional information about this transaction. Our business consists of our Hospital Operations and other (“Hospital Operations”) segment, our Ambulatory Care segment and our Conifer segment. Our Hospital Operations segment is comprised of our acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro‑hospitals and physician practices. Our Ambulatory Care segment is comprised of the operations of USPI, which holds indirect ownership interests in and manages ambulatory surgery centers and surgical hospitals. Our Conifer segment provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Almost all of the services comprising the operations of our Conifer segment are provided by Conifer Health Solutions, LLC or by one of its direct or indirect wholly owned subsidiaries. This quarterly report supplements our Annual Report on Form 10‑K for the year ended December 31, 2022 (“Annual Report”). As permitted by the Securities and Exchange Commission for interim reporting, we have omitted certain notes and disclosures that substantially duplicate those in our Annual Report. For further information, refer to the audited Consolidated Financial Statements and notes included in our Annual Report. Unless otherwise indicated, all dollar amounts presented in our Condensed Consolidated Financial Statements and these accompanying notes are expressed in millions (except per‑share amounts). We adopted the Financial Accounting Standards Board’s Accounting Standards Update (“ASU”) 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), effective as of January 1, 2022 using the modified retrospective method. Among other amendments, ASU 2020-06 changed the accounting for diluted earnings‑per‑share for convertible instruments and contracts that may be settled in cash or stock. ASU 2020-06 eliminated an entity’s ability to rebut the presumption of share settlement for convertible instruments and contracts that can be partially or fully settled in cash at the issuer’s election. Additionally, ASU 2020-06 requires that the if‑converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. As a result of our adoption of ASU 2020-06, diluted weighted average shares outstanding increased by approximately three million shares for both of the three-month periods ended March 31, 2023 and 2022, and diluted earnings per share available to Tenet common shareholders decreased by $0.07 and $0.01, respectively. Certain prior‑year amounts have been reclassified to conform to the current‑year presentation. Contract liabilities – long‑term are no longer significant enough to present separately. These obligations are now included in other long‑term liabilities in the accompanying Condensed Consolidated Balance Sheets. Although our Condensed Consolidated Financial Statements and these related notes are unaudited, we believe all adjustments considered necessary for a fair presentation have been included and are of a normal recurring nature. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires us to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Actual results may vary from those estimates. The financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from the amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public. Operating results for the three‑month period ended March 31, 2023 are not necessarily indicative of the results that may be expected for the full year. Reasons for this include, but are not limited to: the impact of the COVID‑19 pandemic on our operations, business, financial condition and cash flows; the impact of the demand for, and availability of, qualified medical personnel on compensation costs; the impact of cybersecurity incidents on our operations; overall revenue and cost trends, particularly the timing and magnitude of price changes; fluctuations in contractual allowances and cost report settlements and valuation allowances; managed care contract negotiations, settlements or terminations and payer consolidations; trends in patient accounts receivable collectability and associated implicit price concessions; fluctuations in interest rates; levels of malpractice insurance expense and settlement trends; impairment of long‑lived assets and goodwill; restructuring charges; losses, costs and insurance recoveries related to cybersecurity incidents, natural disasters and weather‑related occurrences; litigation and investigation costs; acquisitions and dispositions of facilities and other assets; gains (losses) on sales, consolidation and deconsolidation of facilities; income tax rates and deferred tax asset valuation allowance activity; changes in estimates of accruals for annual incentive compensation; the timing and amounts of stock option and restricted stock unit grants to employees and directors; gains (losses) from early extinguishment of debt; and changes in occupancy levels and patient volumes. Our hospitals and outpatient facilities are subject to various factors that affect our service mix, revenue mix and patient volumes and, thereby, impact our net patient service revenues and results of operations. These factors include, among others: changes in federal, state and local healthcare and business regulations; changes in general economic conditions nationally and regionally, including inflation and the impacts of the COVID-19 pandemic and other factors on business conditions, the economy and financial markets; the number of uninsured and underinsured individuals in local communities treated at our facilities; disease hotspots and seasonal cycles of illness; climate and weather conditions; physician recruitment, satisfaction, retention and attrition; advances in technology and treatments that reduce length of stay or permit procedures to be performed in an outpatient rather than inpatient setting; local healthcare competitors; utilization pressure by managed care organizations, as well as managed care contract negotiations or terminations; performance data on quality measures and patient satisfaction, as well as standard charges for services; any unfavorable publicity about us, or our joint venture partners, that impacts our relationships with physicians and patients; and changing consumer behavior, including with respect to the timing of elective procedures. These considerations apply to year‑to‑year comparisons as well. COVID ‑ 19 Pandemic The COVID‑19 pandemic has impacted all three segments of our business, as well as our patients, communities and employees, to varying degrees since March 2020. Throughout this time, federal, state and local authorities have undertaken several actions designed to assist healthcare providers in providing care to COVID‑19 and other patients and to mitigate the adverse economic impact of the pandemic. Among other things, federal legislation (collectively, the “COVID Acts”) authorized aggregate grant payments of $178 billion to be distributed through the Public Health and Social Services Emergency Fund (“PRF”) to healthcare providers who experienced lost revenues and increased expenses as a result of the COVID‑19 pandemic. The COVID Acts also revised the Medicare accelerated payment program (“MAPP”). Our participation in these programs and the related accounting policies are summarized below. Grant Income– Our Hospital Operations and Ambulatory Care segments received cash payments from the PRF and state grant programs of $4 million and $1 million, respectively, during the three months ended March 31, 2022. These grant funds are included in cash flows from operating activities in our condensed consolidated statements of cash flows. No additional funds were received during the three months ended March 31, 2023. To receive distributions, providers must agree to certain terms and conditions, including, among other things, that the funds would be used for lost revenues and unreimbursed pandemic ‑ related costs as defined by the U.S. Department of Health and Human Services (“HHS”), and that the providers will not seek collection of out ‑ of ‑ pocket payments from a COVID ‑ 19 patient that are greater than what the patient would have otherwise been required to pay if the care had been provided by an in ‑ network provider. All recipients of PRF payments are required to comply with the reporting requirements described in the terms and conditions and as determined by the Secretary of HHS. PRF funds not utilized by the established deadlines, generally 12 to 18 months after receipt, will be recouped by HHS. We recognize grant payments as income when there is reasonable assurance that we have complied with the conditions associated with the grant. The estimates we use to recognize grant income could change materially in the future based on our operating performance or fluctuations in the severity of COVID‑19 outbreaks at individual locations, as well as the government’s grant compliance guidance. The table below summarizes grant income recognized by our Hospital Operations and Ambulatory Care segments, which is presented in grant income in our condensed consolidated statements of operations: Three Months Ended March 31, 2023 2022 Grant income recognized from COVID-19 relief programs: Included in grant income: Hospital Operations $ 3 $ 4 Ambulatory Care — 2 $ 3 $ 6 At March 31, 2023 and December 31, 2022, we had remaining deferred grant payment balances of $4 million and $7 million, respectively, which amounts were recorded in other current liabilities in the accompanying Condensed Consolidated Balance Sheets for those periods. Medicare Accelerated Payment Program (MAPP)– In certain circumstances, when a healthcare facility is experiencing financial difficulty due to delays in receiving payment for the Medicare services it provided, it may be eligible for an accelerated or advance payment pursuant to the MAPP. The COVID Acts revised the MAPP to disburse payments to healthcare providers more quickly and to allow recipients to retain the advance payments for one year from the date of receipt before recoupment commenced through offsets of Medicare claims payments. Recipients were also permitted to repay the advance payments at any time. Our Hospital Operations and Ambulatory Care segments both received advance payments from the MAPP following its expansion under the COVID Acts in the year ended December 31, 2020; however, no additional advances were received during the three months ended March 31, 2023 or 2022. Advances received by our Hospital Operations and Ambulatory Care segments were recouped through reductions of their respective Medicare claims payments. Amounts recouped from our Hospital Operations segment and those facilities in our Ambulatory Care segment that we consolidate, together with any amounts we voluntarily repaid in advance of recoupment, are presented in cash flows from operating activities in our condensed consolidated statements of cash flows. During the three months ended March 31, 2022, $194 million of advances received in prior periods by our Hospital Operations segment and less than $1 million of advances received in prior periods by those facilities in our Ambulatory Care segment that we consolidate were repaid or recouped. No advances were recouped or repaid during the three months ended March 31, 2023, and there was no outstanding liability related to MAPP advances at March 31, 2023 or December 31, 2022. Leases During the three months ended March 31, 2022, we sold several medical office buildings held in our Hospital Operations segment for net cash proceeds of $147 million and concurrently entered into operating lease agreements to continue use of the facilities. We recognized a gain of $69 million from the sale of these buildings, included in other operating expenses, net in the accompanying Condensed Consolidated Statement of Operations, and we recognized right-of-use assets and operating lease obligations of $103 million, in each case in the three months ended March 31, 2022. During the three months ended March 31, 2023 and 2022, we recorded right‑of‑use assets related to non‑cancellable finance leases of $19 million and $18 million, respectively, and related to non‑cancellable operating leases of $44 million and $187 million, respectively. Cash and Cash Equivalents We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were $766 million and $858 million at March 31, 2023 and December 31, 2022, respectively. At March 31, 2023 and December 31, 2022, our book overdrafts were $139 million and $266 million, respectively, which were classified as accounts payable. At March 31, 2023 and December 31, 2022, $122 million and $140 million, respectively, of total cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets were intended for the operations of our insurance‑related subsidiaries. Also at March 31, 2023 and December 31, 2022, we had $63 million and $196 million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $57 million and $191 million, respectively, were included in accounts payable. Other Intangible Assets The following table provides information regarding other intangible assets, which were included in the accompanying Condensed Consolidated Balance Sheets: Gross Accumulated Net Book Value At March 31, 2023: Other intangible assets with finite useful lives: Capitalized software costs $ 1,759 $ (1,202) $ 557 Contracts 294 (150) 144 Other 92 (77) 15 Total other intangible assets with finite lives 2,145 (1,429) 716 Other intangible assets with indefinite useful lives: Trade names 105 — 105 Contracts 605 — 605 Other 6 — 6 Total other intangible assets with indefinite lives 716 — 716 Total other intangible assets $ 2,861 $ (1,429) $ 1,432 At December 31, 2022: Other intangible assets with finite useful lives: Capitalized software costs $ 1,751 $ (1,206) $ 545 Contracts 295 (146) 149 Other 92 (76) 16 Total other intangible assets with finite lives 2,138 (1,428) 710 Other intangible assets with indefinite useful lives: Trade names 105 — 105 Contracts 603 — 603 Other 6 — 6 Total other intangible assets with indefinite lives 714 — 714 Total other intangible assets $ 2,852 $ (1,428) $ 1,424 Estimated future amortization of intangibles with finite useful lives at March 31, 2023 was as follows: Nine Months Ending Years Ending Later Years December 31, Total 2023 2024 2025 2026 2027 Amortization of intangible assets $ 716 $ 124 $ 123 $ 101 $ 88 $ 71 $ 209 We recognized amortization expense of $42 million and $29 million in the accompanying Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022, respectively. Other Current Assets The principal components of other current assets in the accompanying Condensed Consolidated Balance Sheets were as follows: March 31, 2023 December 31, 2022 Prepaid expenses $ 380 $ 400 Contract assets 202 200 California provider fee program receivables 311 367 Receivables from other government programs 152 187 Guarantees 187 143 Non-patient receivables 354 390 Other 85 88 Total other current assets $ 1,671 $ 1,775 Investments in Unconsolidated Affiliates As of March 31, 2023, we controlled 313 of the facilities within our Ambulatory Care segment and, therefore, consolidate their results. We account for many of the facilities our Ambulatory Care segment holds ownership interests in (156 of 469), as well as additional companies in which our Hospital Operations segment holds ownership interests, under the equity method as investments in unconsolidated affiliates and report only our share of net income as equity in earnings of unconsolidated affiliates in our condensed consolidated statements of operations. Summarized financial information for these equity method investees is included in the following table. For investments acquired during the reported periods, amounts in the table include 100% of the investee’s results beginning on the date of our acquisition of the investment. Three Months Ended March 31, 2023 2022 Net operating revenues $ 783 $ 769 Net income $ 185 $ 169 Net income available to the investees $ 107 $ 98

ACCOUNTS RECEIVABLE

ACCOUNTS RECEIVABLE	3 Months Ended
	Mar. 31, 2023
Accounts Receivable Additional Disclosures [Abstract]
ACCOUNTS RECEIVABLE	ACCOUNTS RECEIVABLE The principal components of accounts receivable are presented in the table below: March 31, 2023 December 31, 2022 Patient accounts receivable $ 2,689 $ 2,746 Estimated future recoveries 150 149 Cost report settlements receivable, net of payables and valuation allowances 44 48 Accounts receivable, net $ 2,883 $ 2,943 We participate in various provider fee programs, which help reduce the amount of uncompensated care from indigent patients and those covered by Medicaid. The following table summarizes the amount and classification of assets and liabilities in the accompanying Condensed Consolidated Balance Sheets related to California’s provider fee program: March 31, 2023 December 31, 2022 Assets: Other current assets $ 311 $ 367 Investments and other assets $ 261 $ 197 Liabilities: Other current liabilities $ 146 $ 145 Other long-term liabilities $ 55 $ 63 Uninsured and Charity Patient Costs The following table presents our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our uninsured and charity patients: Three Months Ended March 31, 2023 2022 Estimated costs for: Uninsured patients $ 123 $ 122 Charity care patients 24 21 Total $ 147 $ 143

CONTRACT BALANCES

CONTRACT BALANCES	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
CONTRACT BALANCES	CONTRACT BALANCES Hospital Operations Segment Amounts related to services provided to patients for which we have not billed and that do not meet the conditions of unconditional right to payment at the end of the reporting period are contract assets. For our Hospital Operations segment, our contract assets include services that we have provided to patients who are still receiving inpatient care in our facilities at the end of the reporting period. Our Hospital Operations segment’s contract assets were included in other current assets in the accompanying Condensed Consolidated Balance Sheets at March 31, 2023 and December 31, 2022. Approximately 88% of our Hospital Operations segment’s contract assets meet the conditions for unconditional right to payment and are reclassified to patient receivables within 90 days. As discussed in Note 1, our Hospital Operations segment received advance payments from the MAPP following its expansion under the COVID Acts in 2020; however, no additional advances were received during the three months ended March 31, 2023 or 2022. All remaining MAPP advances received by our Hospital Operations segment were either repaid or recouped during 2022 and 2021, which resulted in no outstanding liability at March 31, 2023 and December 31, 2022. The opening and closing balances of contract assets and contract liabilities, as well as their classification in our condensed consolidated balance sheets, for our Hospital Operations segment were as follows: Contract Assets Contract Liabilities – Current Advances from Medicare December 31, 2022 $ 185 $ — March 31, 2023 185 — Increase $ — $ — December 31, 2021 $ 181 $ 876 March 31, 2022 169 682 Decrease $ (12) $ (194) During the three months ended March 31, 2022, $194 million of Medicare advance payments included in the opening contract liabilities balance for our Hospital Operations segment were recouped through a reduction of our Medicare claims payments. Ambulatory Care Segment Our Ambulatory Care segment also received advance payments from the MAPP following its expansion in 2020; however, no additional advances were received during the three months ended March 31, 2023 or 2022. All remaining MAPP advances received by our Ambulatory Care segment were either repaid or recouped during 2022 and 2021, which resulted in no outstanding liability at March 31, 2023 and December 31, 2022. Conifer Segment Conifer enters into contracts with clients to provide revenue cycle management and other services, such as value‑based care, consulting and engagement solutions. The payment terms and conditions in Conifer’s client contracts vary. In some cases, clients are invoiced in advance and (for other than fixed‑price fee arrangements) a true‑up to the actual fee is included on a subsequent invoice. In other cases, payment is due in arrears. In addition, some contracts contain performance incentives, penalties and other forms of variable consideration. When the timing of Conifer’s delivery of services is different from the timing of payments made by its clients, Conifer recognizes either unbilled revenue (performance precedes contractual right to invoice the client) or deferred revenue (client payment precedes Conifer service performance). In the following table, clients that prepay prior to obtaining control/benefit of services are represented by deferred contract revenue until the performance obligations are satisfied. Unbilled revenue represents arrangements in which Conifer has provided services to a client, and the client has obtained control/benefit of these services prior to the contractual invoice date. Contracts with payment in arrears are recognized as receivables in the month the services are performed. The opening and closing balances of Conifer’s receivables, contract assets, and current and long‑term contract liabilities were as follows: Receivables Contract Assets – Unbilled Revenue Contract Liabilities – Current Contract Liabilities – Long-Term December 31, 2022 $ 37 $ 15 $ 110 $ 13 March 31, 2023 57 17 76 13 Increase (decrease) $ 20 $ 2 $ (34) $ — December 31, 2021 $ 28 $ 18 $ 79 $ 15 March 31, 2022 34 15 90 14 Increase (decrease) $ 6 $ (3) $ 11 $ (1) The differences between the opening and closing balances of Conifer’s contract assets and contract liabilities are primarily related to prepayments for those clients who are billed in advance, changes in estimates related to metric‑based services, and up‑front integration services that are typically not distinct and are, therefore, recognized over the performance obligation period to which they relate. Our Conifer segment’s receivables and contract assets at March 31, 2023 and December 31, 2022 were reported as part of other current assets in the accompanying Condensed Consolidated Balance Sheets, and its current and long‑term contract liabilities on those dates were reported as part of contract liabilities and other long‑term liabilities respectively. In the three months ended March 31, 2023 and 2022, Conifer recognized $64 million and $49 million, respectively, of revenue that was included in the opening current deferred revenue liability. This revenue consists primarily of prepayments for those clients who are billed in advance, changes in estimates related to metric‑based services, and up‑front integration services that are recognized over the service period. Contract Costs During both of the three‑month periods ended March 31, 2023 and 2022, we recognized amortization expense related to deferred contract setup costs of $1 million. At both March 31, 2023 and December 31, 2022, the unamortized client contract costs were $24 million and were presented as part of investments and other assets in the accompanying Condensed Consolidated Balance Sheets. Net operating revenues for our Hospital Operations and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our Compact with Uninsured Patients and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to health systems, individual hospitals and physician practices. The table below presents our sources of net operating revenues: Three Months Ended March 31, 2023 2022 Hospital Operations: Net patient service revenues from hospitals and related outpatient facilities: Medicare $ 613 $ 619 Medicaid 280 249 Managed care (1) 2,503 2,438 Uninsured 31 38 Indemnity and other 140 164 Total 3,567 3,508 Other revenues (2) 332 290 Hospital Operations total prior to inter-segment eliminations 3,899 3,798 Ambulatory Care 905 738 Conifer 324 324 Inter-segment eliminations (107) (115) Net operating revenues $ 5,021 $ 4,745 (1) Includes Medicare and Medicaid managed care programs. (2) Primarily physician practices revenues. Revenues related to the Texas Comprehensive Hospital Increase Reimbursement Program (“CHIRP”) are presented in managed care net patient service revenues in the table above. Amounts we were assessed to support CHIRP following its approval in 2022 were presented in Medicaid revenues in prior periods, but have been reclassified to conform to the current‑year presentation in the same payer group as the revenues to more clearly reflect the results of our participation in this program. Assessments to support CHIRP totaled $26 million and $57 million for the three months ended March 31, 2023 and 2022, respectively. The following tables present the composition of net operating revenues for our Ambulatory Care and Conifer segments: Three Months Ended March 31, 2023 2022 Ambulatory Care: Net patient service revenues $ 868 $ 704 Management fees 30 29 Revenue from other sources 7 5 Ambulatory Care net operating revenues $ 905 $ 738 Three Months Ended March 31, 2023 2022 Conifer: Revenue cycle services – Tenet $ 104 $ 112 Revenue cycle services – other clients 199 189 Other services – Tenet 3 3 Other services – other clients 18 20 Conifer net operating revenues $ 324 $ 324 Performance Obligations The following table includes Conifer’s revenue that is expected to be recognized in the future related to performance obligations that are unsatisfied, or partially unsatisfied, at the end of the reporting period: Nine Months Ending Years Ending Later Years December 31, Total 2023 2024 2025 2026 2027 Performance obligations $ 5,926 $ 500 $ 603 $ 603 $ 603 $ 603 $ 3,014 The amounts in the table above primarily consist of revenue cycle management fixed fees, which are typically recognized ratably as the performance obligation is satisfied. The estimated revenue does not include volume‑ or contingency‑based contracts, variable‑based rate escalators, performance incentives, penalties or other variable consideration that is considered constrained. Conifer’s contract with Catholic Health Initiatives (“CHI”), a minority interest owner of Conifer Health Solutions, LLC, represents the majority of the fixed‑fee revenue related to remaining performance obligations. Conifer’s contract term with CHI ends December 31, 2032.

ASSETS AND LIABILITIES HELD FOR

ASSETS AND LIABILITIES HELD FOR SALE	3 Months Ended
	Mar. 31, 2023
Discontinued Operation, Additional Disclosures [Abstract]
ASSETS AND LIABILITIES HELD FOR SALE	ASSETS AND LIABILITIES HELD FOR SALE In January 2023, we entered into a definitive agreement to sell our 51% ownership interest in San Ramon Regional Medical Center and certain related operations (“San Ramon RMC”) to John Muir Health. As a result, the assets and liabilities associated with San Ramon RMC were classified as held for sale in the accompanying Condensed Consolidated Balance Sheet and totaled $142 million and $23 million, respectively, at March 31, 2023. We expect the transaction to be completed in 2023, subject to regulatory review and customary closing conditions. Assets and liabilities classified as held for sale were comprised of the following: March 31, 2023 Accounts receivable $ 28 Other current assets 11 Investments and other long-term assets 3 Property and equipment 63 Other intangible assets 6 Goodwill 31 Current liabilities (22) Long-term liabilities (1) Net assets held for sale $ 119

IMPAIRMENT AND RESTRUCTURING CH

IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS	3 Months Ended
	Mar. 31, 2023
Restructuring Costs and Asset Impairment Charges [Abstract]
IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS	IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION ‑ RELATED COSTS Our impairment tests presume stable, improving or, in some cases, declining operating results in our facilities, which are based on programs and initiatives being implemented that are designed to achieve each facility’s most recent projections. If these projections are not met, or negative trends occur that impact our future outlook, future impairments of long‑lived assets and goodwill may occur, and we may incur additional restructuring charges, which could be material. At March 31, 2023, our operations consisted of three reportable segments – Hospital Operations, Ambulatory Care and Conifer. Our segments are reporting units used to perform our goodwill impairment analysis. We periodically incur costs to implement restructuring efforts for specific operations, which are recorded in our statement of operations as they are incurred. Our restructuring plans focus on various aspects of operations, including aligning our operations in the most strategic and cost‑effective structure, such as the establishment of support operations at our GBC. Certain restructuring and acquisition‑related costs are based on estimates. Changes in estimates are recognized as they occur. During the three months ended March 31, 2023, we recorded impairment and restructuring charges and acquisition‑related costs of $21 million, consisting of $18 million of restructuring charges, $1 million of impairment charges and $2 million of acquisition‑related costs. Restructuring charges consisted of $4 million of employee severance costs, $4 million related to the transition of various administrative functions to our GBC, $3 million of contract and lease termination fees, and $7 million of other restructuring costs. Acquisition‑related costs consisted of $2 million of transaction costs. During the three months ended March 31, 2022, we recorded impairment and restructuring charges and acquisition‑related costs of $16 million, consisting of $12 million of restructuring charges, $1 million of impairment charges and $3 million of acquisition‑related costs. Restructuring charges consisted of $5 million of employee severance costs, $2 million related to the transition of various administrative functions to our GBC and $5 million of other restructuring costs. Acquisition‑related costs consisted of $3 million of transaction costs.

LONG-TERM DEBT

LONG-TERM DEBT	3 Months Ended
	Mar. 31, 2023
Long-Term Debt and Lease Obligation [Abstract]
LONG-TERM DEBT	LONG-TERM DEBT The table below presents our long‑term debt included in the accompanying Condensed Consolidated Balance Sheets: March 31, 2023 December 31, 2022 Senior unsecured notes: 6.125% due 2028 $ 2,500 $ 2,500 6.875% due 2031 362 362 Senior secured first lien notes: 4.625% due July 2024 756 756 4.625% due September 2024 589 589 4.875% due 2026 2,100 2,100 5.125% due 2027 1,500 1,500 4.625% due 2028 600 600 4.250% due 2029 1,400 1,400 4.375% due 2030 1,450 1,450 6.125% due 2030 2,000 2,000 Senior secured second lien notes: 6.250% due 2027 1,500 1,500 Finance leases, mortgages and other notes 451 453 Unamortized issue costs and note discounts (125) (131) Total long-term debt 15,083 15,079 Less: Current portion 148 145 Long-term debt, net of current portion $ 14,935 $ 14,934 Senior Unsecured and Senior Secured Notes At March 31, 2023, we had outstanding senior unsecured notes and senior secured notes with aggregate principal amounts outstanding of $14.757 billion. These notes have fixed interest rates ranging from 4.250% to 6.875% and generally require semi-annual interest payments in arrears. The principal and any accrued but unpaid interest is due upon the maturity date of the respective notes, which dates are staggered from July 2024 through November 2031. Credit Agreement We have a senior secured revolving credit facility that provides for revolving loans in an aggregate principal amount of up to $1.500 billion with a $200 million subfacility for standby letters of credit. We amended our credit agreement (as amended to date, the “Credit Agreement”) in March 2022 to, among other things, (1) decrease the aggregate revolving credit commitments from the previous limit of $1.900 billion to aggregate revolving credit commitments not to exceed $1.500 billion, subject to borrowing availability, (2) extend the scheduled maturity date to March 16, 2027, and (3) replace the London Interbank Offered Rate (LIBOR) with the Term Secured Overnight Financing Rate (“SOFR”) and Daily Simple SOFR (each, as defined in the Credit Agreement) as the reference interest rate. Outstanding revolving loans accrue interest depending on the type of loan at either (a) a base rate plus an applicable margin ranging from 0.25% to 0.75% per annum or (b) Term SOFR, Daily Simple SOFR or the Euro Interbank Offered Rate (EURIBOR) (each, as defined in the Credit Agreement) plus an applicable margin ranging from 1.25% to 1.75% per annum and (in the case of Term SOFR and Daily Simple SOFR only) a credit spread adjustment of 0.10%, in each case based on available credit. An unused commitment fee payable on the undrawn portion of the revolving loans ranges from 0.25% to 0.375% per annum based on available credit. Our borrowing availability is based on a specified percentage of eligible inventory and accounts receivable, including self‑pay accounts. At March 31, 2023, we had no cash borrowings outstanding under the Credit Agreement, and we had less than $1 million of standby letters of credit outstanding. Based on our eligible receivables, $1.500 billion was available for borrowing under the Credit Agreement at March 31, 2023. Letter of Credit Facility We have a letter of credit facility (as amended to date, the “LC Facility”) that provides for the issuance, from time to time, of standby and documentary letters of credit in an aggregate principal amount of up to $200 million. The scheduled maturity date of the LC Facility is September 12, 2024. Drawings under any letter of credit issued under the LC Facility that we have not reimbursed within three business days after notice thereof accrue interest at a base rate plus a margin of 0.50% per annum. An unused commitment fee is payable at an initial rate of 0.25% per annum with a step up to 0.375% per annum should our secured‑debt‑to‑EBITDA ratio equal or exceed 3.00 to 1.00 at the end of any fiscal quarter. A fee on the aggregate outstanding amount of issued but undrawn letters of credit accrues at a rate of 1.50% per annum. An issuance fee equal to 0.125% per annum of the aggregate face amount of each outstanding letter of credit is payable to the account of the issuer of the related letter of credit. The LC Facility is subject to an effective maximum secured debt covenant of 4.25 to 1.00. At March 31, 2023, we had $116 million of standby letters of credit outstanding under the LC Facility.

GUARANTEES

GUARANTEES	3 Months Ended
	Mar. 31, 2023
Guarantees [Abstract]
GUARANTEES	GUARANTEES At March 31, 2023, the maximum potential amount of future payments under our income guarantees to certain physicians who agree to relocate and revenue collection guarantees to hospital‑based physician groups providing certain services at our hospitals was $207 million. We had a total liability of $187 million recorded for these guarantees included in other current liabilities in the accompanying Condensed Consolidated Balance Sheet at March 31, 2023. At March 31, 2023, we also had issued guarantees of the indebtedness and other obligations of our investees to third parties, the maximum potential amount of future payments under which was approximately $105 million. Of the total, $29 million relates to the obligations of consolidated subsidiaries, which obligations were recorded in the accompanying Condensed Consolidated Balance Sheet at March 31, 2023.

EMPLOYEE BENEFIT PLANS

EMPLOYEE BENEFIT PLANS	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
EMPLOYEE BENEFIT PLANS	EMPLOYEE BENEFIT PLANS Share-Based Compensation Plans The accompanying Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022 include $14 million and $16 million, respectively, of pre-tax compensation costs related to our stock‑based compensation arrangements. Stock Options The following table summarizes information about our outstanding stock options at March 31, 2023: Options Outstanding and Exercisable Range of Exercise Prices Number of Weighted Average Weighted Average $18.99 to $20.609 293,796 4.4 years $ 19.75 $20.61 to $35.430 167,151 5.8 years $ 29.62 460,947 4.9 years $ 23.33 There was no activity related to our stock options during the three months ended March 31, 2023. During the three months ended March 31, 2022, there were 60,051 stock options exercised with an aggregate intrinsic value of $4 million. All outstanding options were vested and exercisable at March 31, 2023 and had an aggregate intrinsic value of $17 million. Restricted Stock Units The following table summarizes activity with respect to restricted stock units (“RSUs”) during the three months ended March 31, 2023: Number of RSUs Weighted Average Grant Unvested at December 31, 2022 1,520,418 $ 66.36 Granted 678,748 $ 62.45 Performance-based adjustment 185,901 $ 48.97 Vested (823,418) $ 52.95 Forfeited (26,660) $ 56.31 Unvested at March 31, 2023 1,534,989 $ 65.58 In the three months ended March 31, 2023, we granted an aggregate of 864,649 RSUs that will vest and settle as follows: • 301,268 RSUs will vest and settle ratably over a three‑year period from the grant date; • 301,268 performance‑based RSUs will vest and settle as described below; • 185,901 RSUs that vested and settled immediately as a result of our level of achievement with respect to performance‑based RSUs granted in 2020; • 42,626 RSUs will vest and settle on the fifth anniversary of the grant date; and • 33,586 RSUs will vest and settle on December 31, 2023. The vesting of the performance-based RSUs granted in the three months ended March 31, 2023 is contingent on our achievement of specified performance goals for the years 2023 to 2025. Provided the goals are achieved, these performance‑based RSUs will vest and settle on the third anniversary of the grant date. The actual number of performance‑based RSUs that could vest will range from 0% to 225% of the 301,268 units granted, depending on our level of achievement with respect to the performance goals. In the three months ended March 31, 2022, we granted an aggregate of 570,080 RSUs that will vest and settle as follows: • 281,955 performance-based RSUs will vest and settle as described below; • 228,239 RSUs will vest and settle ratably over a three‑year period from the grant date; • 53,716 RSUs granted to our former Executive Chairman that were scheduled to vest and be settled ratably over 11 quarterly periods from the grant date; and • 6,170 RSUs will vest and settle evenly on the third and fourth anniversaries of the grant date. The vesting of the performance-based RSUs granted in the three months ended March 31, 2022 is contingent on our achievement of specified performance goals for the years 2022 to 2024. Provided the goals are achieved, these performance‑based RSUs will vest and settle on the third anniversary of the grant date. The actual number of performance‑based RSUs that could vest will range from 0% to 200% of the 281,955 units granted, depending on our level of achievement with respect to the performance goals. The aggregate number of performance-based RSUs granted in 2022 included 53,716 RSUs granted to our former Executive Chairman. These performance-based RSUs, which vested at 100%, and the unvested portion of the 53,716 time-based RSUs granted during the same period vested and settled in October 2022 in accordance with the disability provisions of our stock incentive plan. The fair value of an RSU is based on our share price on the grant date. For certain of the performance ‑ based RSU grants, the number of units that will ultimately vest is subject to adjustment based on the achievement of a market‑based condition. The fair value of these RSUs is estimated through the use of a Monte Carlo simulation. Significant inputs used in our valuation of these RSUs included the following: Three Months Ended March 31, 2023 2022 Expected volatility 53.6% - 65.6% 39.6% - 68.1% Risk-free interest rate 4.5% - 4.8% 1.0% - 1.7% At March 31, 2023, there were $63 million of total unrecognized compensation costs related to RSUs. These costs are expected to be recognized over a weighted average period of 2.2 years. USPI Management Equity Plan USPI maintains a separate restricted stock plan (the “USPI Management Equity Plan”) under which it grants RSUs representing a contractual right to receive one share of USPI’s non‑voting common stock in the future. The vesting of RSUs granted under the plan varies based on the terms of the underlying award agreement. Once the requisite holding period is met, during specified times, the participant can sell the underlying shares to USPI at their estimated fair market value. At our sole discretion, the purchase of any non‑voting common shares can be made in cash or in shares of Tenet’s common stock. The following table summarizes RSU activity under the USPI Management Equity Plan during the three months ended March 31, 2023: Number of RSUs Weighted Average Grant Unvested at December 31, 2022 922,840 $ 34.13 Vested (303,171) $ 34.13 Unvested at March 31, 2023 619,669 $ 34.13

EQUITY

EQUITY	3 Months Ended
	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
EQUITY	EQUITY The following tables present the changes in consolidated equity (dollars in millions, share amounts in thousands): Common Stock Additional Accumulated Accumulated Treasury Noncontrolling Total Equity Shares Issued Par Balances at December 31, 2022 102,247 $ 8 $ 4,778 $ (181) $ (803) $ (2,660) $ 1,317 $ 2,459 Net income — — — — 143 — 74 217 Distributions paid to noncontrolling interests — — — — — — (61) (61) Other comprehensive income — — — 2 — — — 2 Purchases of businesses and noncontrolling interests, net — — 2 — — — 17 19 Repurchases of common stock (906) — — — — (50) — (50) Stock-based compensation expense and issuance of common stock 571 — (6) — — — — (6) Balances at March 31, 2023 101,912 $ 8 $ 4,774 $ (179) $ (660) $ (2,710) $ 1,347 $ 2,580 Common Stock Additional Accumulated Accumulated Treasury Noncontrolling Total Equity Shares Issued Par Balances at December 31, 2021 107,189 $ 8 $ 4,877 $ (233) $ (1,214) $ (2,410) $ 1,026 $ 2,054 Net income — — — — 140 — 46 186 Distributions paid to noncontrolling interests — — — — — — (71) (71) Accretion of redeemable noncontrolling interests — — (95) — — — — (95) Sales of businesses and noncontrolling interests, net — — (7) — — — (1) (8) Stock-based compensation expense and issuance of common stock 499 — (10) — — — — (10) Balances at March 31, 2022 107,688 $ 8 $ 4,765 $ (233) $ (1,074) $ (2,410) $ 1,000 $ 2,056 Noncontrolling Interests Our noncontrolling interests balances at March 31, 2023 and December 31, 2022 were comprised of $131 million and $132 million, respectively, from our Hospital Operations segment, and $1.216 billion and $1.185 billion, respectively, from our Ambulatory Care segment. Our net income available to noncontrolling interests for the three months ended March 31, 2023 and 2022 in the tables above were comprised of $5 million and $3 million, respectively, from our Hospital Operations segment and $69 million and $43 million, respectively, from our Ambulatory Care segment. Share Repurchase Program In October 2022, we announced that our board of directors had authorized the repurchase of up to $1 billion of our common stock through a share repurchase program that expires on December 31, 2024. Under the program, shares can be purchased in the open market or through privately negotiated transactions in a manner consistent with applicable securities laws and regulations, including pursuant to a Rule 10b5-1 plan maintained by the Company, at times and in amounts based on market conditions and other factors. The table below summarizes transactions completed under the repurchase program during the three months ended March 31, 2023: Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Program Maximum Dollar Value of Shares That May Yet be Purchased Under the Program (In Thousands) (In Thousands) (In Millions) January 1 through January 31, 2023 — $ — — $ 750 February 1 through February 28, 2023 — $ — — $ 750 March 1 through March 31, 2023 906 $ 55.03 906 $ 700

NET OPERATING REVENUES

NET OPERATING REVENUES	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
NET OPERATING REVENUES	CONTRACT BALANCES Hospital Operations Segment Amounts related to services provided to patients for which we have not billed and that do not meet the conditions of unconditional right to payment at the end of the reporting period are contract assets. For our Hospital Operations segment, our contract assets include services that we have provided to patients who are still receiving inpatient care in our facilities at the end of the reporting period. Our Hospital Operations segment’s contract assets were included in other current assets in the accompanying Condensed Consolidated Balance Sheets at March 31, 2023 and December 31, 2022. Approximately 88% of our Hospital Operations segment’s contract assets meet the conditions for unconditional right to payment and are reclassified to patient receivables within 90 days. As discussed in Note 1, our Hospital Operations segment received advance payments from the MAPP following its expansion under the COVID Acts in 2020; however, no additional advances were received during the three months ended March 31, 2023 or 2022. All remaining MAPP advances received by our Hospital Operations segment were either repaid or recouped during 2022 and 2021, which resulted in no outstanding liability at March 31, 2023 and December 31, 2022. The opening and closing balances of contract assets and contract liabilities, as well as their classification in our condensed consolidated balance sheets, for our Hospital Operations segment were as follows: Contract Assets Contract Liabilities – Current Advances from Medicare December 31, 2022 $ 185 $ — March 31, 2023 185 — Increase $ — $ — December 31, 2021 $ 181 $ 876 March 31, 2022 169 682 Decrease $ (12) $ (194) During the three months ended March 31, 2022, $194 million of Medicare advance payments included in the opening contract liabilities balance for our Hospital Operations segment were recouped through a reduction of our Medicare claims payments. Ambulatory Care Segment Our Ambulatory Care segment also received advance payments from the MAPP following its expansion in 2020; however, no additional advances were received during the three months ended March 31, 2023 or 2022. All remaining MAPP advances received by our Ambulatory Care segment were either repaid or recouped during 2022 and 2021, which resulted in no outstanding liability at March 31, 2023 and December 31, 2022. Conifer Segment Conifer enters into contracts with clients to provide revenue cycle management and other services, such as value‑based care, consulting and engagement solutions. The payment terms and conditions in Conifer’s client contracts vary. In some cases, clients are invoiced in advance and (for other than fixed‑price fee arrangements) a true‑up to the actual fee is included on a subsequent invoice. In other cases, payment is due in arrears. In addition, some contracts contain performance incentives, penalties and other forms of variable consideration. When the timing of Conifer’s delivery of services is different from the timing of payments made by its clients, Conifer recognizes either unbilled revenue (performance precedes contractual right to invoice the client) or deferred revenue (client payment precedes Conifer service performance). In the following table, clients that prepay prior to obtaining control/benefit of services are represented by deferred contract revenue until the performance obligations are satisfied. Unbilled revenue represents arrangements in which Conifer has provided services to a client, and the client has obtained control/benefit of these services prior to the contractual invoice date. Contracts with payment in arrears are recognized as receivables in the month the services are performed. The opening and closing balances of Conifer’s receivables, contract assets, and current and long‑term contract liabilities were as follows: Receivables Contract Assets – Unbilled Revenue Contract Liabilities – Current Contract Liabilities – Long-Term December 31, 2022 $ 37 $ 15 $ 110 $ 13 March 31, 2023 57 17 76 13 Increase (decrease) $ 20 $ 2 $ (34) $ — December 31, 2021 $ 28 $ 18 $ 79 $ 15 March 31, 2022 34 15 90 14 Increase (decrease) $ 6 $ (3) $ 11 $ (1) The differences between the opening and closing balances of Conifer’s contract assets and contract liabilities are primarily related to prepayments for those clients who are billed in advance, changes in estimates related to metric‑based services, and up‑front integration services that are typically not distinct and are, therefore, recognized over the performance obligation period to which they relate. Our Conifer segment’s receivables and contract assets at March 31, 2023 and December 31, 2022 were reported as part of other current assets in the accompanying Condensed Consolidated Balance Sheets, and its current and long‑term contract liabilities on those dates were reported as part of contract liabilities and other long‑term liabilities respectively. In the three months ended March 31, 2023 and 2022, Conifer recognized $64 million and $49 million, respectively, of revenue that was included in the opening current deferred revenue liability. This revenue consists primarily of prepayments for those clients who are billed in advance, changes in estimates related to metric‑based services, and up‑front integration services that are recognized over the service period. Contract Costs During both of the three‑month periods ended March 31, 2023 and 2022, we recognized amortization expense related to deferred contract setup costs of $1 million. At both March 31, 2023 and December 31, 2022, the unamortized client contract costs were $24 million and were presented as part of investments and other assets in the accompanying Condensed Consolidated Balance Sheets. Net operating revenues for our Hospital Operations and Ambulatory Care segments primarily consist of net patient service revenues, principally for patients covered by Medicare, Medicaid, managed care and other health plans, as well as certain uninsured patients under our Compact with Uninsured Patients and other uninsured discount and charity programs. Net operating revenues for our Conifer segment primarily consist of revenues from providing revenue cycle management services to health systems, individual hospitals and physician practices. The table below presents our sources of net operating revenues: Three Months Ended March 31, 2023 2022 Hospital Operations: Net patient service revenues from hospitals and related outpatient facilities: Medicare $ 613 $ 619 Medicaid 280 249 Managed care (1) 2,503 2,438 Uninsured 31 38 Indemnity and other 140 164 Total 3,567 3,508 Other revenues (2) 332 290 Hospital Operations total prior to inter-segment eliminations 3,899 3,798 Ambulatory Care 905 738 Conifer 324 324 Inter-segment eliminations (107) (115) Net operating revenues $ 5,021 $ 4,745 (1) Includes Medicare and Medicaid managed care programs. (2) Primarily physician practices revenues. Revenues related to the Texas Comprehensive Hospital Increase Reimbursement Program (“CHIRP”) are presented in managed care net patient service revenues in the table above. Amounts we were assessed to support CHIRP following its approval in 2022 were presented in Medicaid revenues in prior periods, but have been reclassified to conform to the current‑year presentation in the same payer group as the revenues to more clearly reflect the results of our participation in this program. Assessments to support CHIRP totaled $26 million and $57 million for the three months ended March 31, 2023 and 2022, respectively. The following tables present the composition of net operating revenues for our Ambulatory Care and Conifer segments: Three Months Ended March 31, 2023 2022 Ambulatory Care: Net patient service revenues $ 868 $ 704 Management fees 30 29 Revenue from other sources 7 5 Ambulatory Care net operating revenues $ 905 $ 738 Three Months Ended March 31, 2023 2022 Conifer: Revenue cycle services – Tenet $ 104 $ 112 Revenue cycle services – other clients 199 189 Other services – Tenet 3 3 Other services – other clients 18 20 Conifer net operating revenues $ 324 $ 324 Performance Obligations The following table includes Conifer’s revenue that is expected to be recognized in the future related to performance obligations that are unsatisfied, or partially unsatisfied, at the end of the reporting period: Nine Months Ending Years Ending Later Years December 31, Total 2023 2024 2025 2026 2027 Performance obligations $ 5,926 $ 500 $ 603 $ 603 $ 603 $ 603 $ 3,014 The amounts in the table above primarily consist of revenue cycle management fixed fees, which are typically recognized ratably as the performance obligation is satisfied. The estimated revenue does not include volume‑ or contingency‑based contracts, variable‑based rate escalators, performance incentives, penalties or other variable consideration that is considered constrained. Conifer’s contract with Catholic Health Initiatives (“CHI”), a minority interest owner of Conifer Health Solutions, LLC, represents the majority of the fixed‑fee revenue related to remaining performance obligations. Conifer’s contract term with CHI ends December 31, 2032.

INSURANCE

INSURANCE	3 Months Ended
	Mar. 31, 2023
Property and Professional and General Liablity Insurance [Abstract]
INSURANCE	INSURANCE Property Insurance We have property, business interruption and related insurance coverage to mitigate the financial impact of catastrophic events or perils that is subject to deductible provisions based on the terms of the policies. These policies are issued on an occurrence basis. For both the policy periods of April 1, 2022 through March 31, 2023 and April 1, 2023 through March 31, 2024, we have coverage totaling $850 million per occurrence, after deductibles and exclusions, with annual aggregate sub‑limits of $100 million for floods, $200 million for earthquakes in California, $200 million for all other earthquakes and a per‑occurrence sub‑limit of $200 million per named windstorm with no annual aggregate. With respect to fires and other perils, excluding floods, earthquakes and named windstorms, the total $850 million limit of coverage per occurrence applies. Deductibles are 5% of insured values for earthquakes in California and named windstorms, and 2% of insured values for earthquakes in the New Madrid fault zone, each with a maximum deductible per claim of $25 million. All other covered losses are subject to a minimum deductible of $5 million per occurrence. We also purchase cyber liability insurance from third parties. In April 2022, we experienced a cybersecurity incident that temporarily disrupted a subset of our acute care operations and involved the exfiltration of certain confidential company and patient information (the “Cybersecurity Incident”). We have filed a claim within our policy limits for the costs to remediate the issues, lost revenues from the associated business interruption and other related expenses. Insurance recoveries of $31 million related to this claim were received during the three months ended March 31, 2023, $27 million of which were recorded as net operating revenues. Professional and General Liability Reserves We are self‑insured for the majority of our professional and general liability claims, and we purchase insurance from third‑parties to cover catastrophic claims. At March 31, 2023 and December 31, 2022, the aggregate current and long‑term professional and general liability reserves in the accompanying Condensed Consolidated Balance Sheets were $1.066 billion and $1.045 billion, respectively. These reserves include the reserves recorded by our captive insurance subsidiaries and our self‑insured retention reserves recorded based on modeled estimates for the portion of our professional and general liability risks, including incurred but not reported claims, for which we do not have insurance coverage. Malpractice expense of $91 million and $81 million was included in other operating expenses, net, in the accompanying Condensed Consolidated Statements of Operations for the three months ended March 31, 2023 and 2022, respectively.

CLAIMS AND LAWSUITS

CLAIMS AND LAWSUITS	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
CLAIMS AND LAWSUITS	CLAIMS AND LAWSUITSWe operate in a highly regulated and litigious industry. Healthcare companies are subject to numerous investigations by various governmental agencies. Further, private parties have the right to bring qui tam or “whistleblower” lawsuits against companies that allegedly submit false claims for payments to, or improperly retain overpayments from, the government and, in some states, private payers. We and our subsidiaries have received inquiries in recent years from government agencies, and we may receive similar inquiries in future periods. We are also subject to class action lawsuits, employment‑related claims and other legal actions in the ordinary course of business. Some of these actions may involve large demands, as well as substantial defense costs. We cannot predict the outcome of current or future legal actions against us or the effect that judgments or settlements in such matters may have on us. We record accruals for estimated losses relating to claims and lawsuits when available information indicates that a loss is probable and we can reasonably estimate the amount of the loss or a range of loss. Significant judgment is required in both the determination of the probability of a loss and the determination as to whether a loss is reasonably estimable. These determinations are updated at least quarterly and are adjusted to reflect the effects of negotiations, settlements, rulings, advice of legal counsel and technical experts, and other information and events pertaining to a particular matter, but are subject to significant uncertainty regarding numerous factors that could affect the ultimate loss levels. If a loss on a material matter is reasonably possible and estimable, we disclose an estimate of the loss or a range of loss. In cases where we have not disclosed an estimate, we have concluded that the loss is either not reasonably possible or the loss, or a range of loss, is not reasonably estimable, based on available information. Given the inherent uncertainties associated with these matters, especially those involving governmental agencies, and the indeterminate damages sought in some cases, we are unable to predict the ultimate liability we may incur from these matters, and an adverse outcome in one or more of these matters could be material to our results of operations or cash flows for any particular reporting period. Government Investigation of Detroit Medical Center Detroit Medical Center (“DMC”) is subject to an ongoing investigation commenced in October 2017 by the U.S. Attorney’s Office for the Eastern District of Michigan and the Civil Division of the U.S. Department of Justice (“DOJ”) for potential violations of the Stark law, the Medicare and Medicaid anti‑kickback and antifraud and abuse amendments codified under Section 1128B(b) of the Social Security Act, and the federal False Claims Act related to DMC’s employment of nurse practitioners and physician assistants (“Mid‑Level Practitioners”) from 2006 through 2017. As previously disclosed, a media report was published in August 2017 alleging that 14 Mid‑Level Practitioners were terminated by DMC earlier in 2017 due to compliance concerns. The DOJ issued a civil investigative demand to DMC for documents and interrogatories in September 2021. In January 2023, we reached a settlement in principle with the DOJ to resolve this matter, subject to certain conditions, and were fully reserved for such potential settlement at March 31, 2023 and December 31, 2022. Other Matters We are also subject to claims and lawsuits arising in the ordinary course of business, including potential claims related to, among other things, the care and treatment provided at our hospitals and outpatient facilities, the application of various federal and state labor and privacy laws, tax audits and other matters. Although the results of these claims and lawsuits cannot be predicted with certainty, we believe that the ultimate resolution of these ordinary course claims and lawsuits will not have a material effect on our business or financial condition. New claims or inquiries may be initiated against us from time to time. These matters could (1) require us to pay substantial damages or amounts in judgments or settlements, which, individually or in the aggregate, could exceed amounts, if any, that may be recovered under our insurance policies where coverage applies and is available, (2) cause us to incur substantial expenses, (3) require significant time and attention from our management, and (4) cause us to close or sell hospitals or otherwise modify the way we conduct business. The following table presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs: Balances at Litigation and Cash Other Balances at Three Months Ended March 31, 2023 $ 51 $ 4 $ (5) $ — $ 50 Three Months Ended March 31, 2022 $ 78 $ 20 $ (36) $ 2 $ 64

REDEEMABLE NONCONTROLLING INTER

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES	3 Months Ended
	Mar. 31, 2023
Noncontrolling Interest [Abstract]
REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES	REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIESWe had a put/call agreement (the “Baylor Put/Call Agreement”) with Baylor that contained put and call options with respect to the 5% ownership interest Baylor previously held in USPI (the “Baylor Shares”). Based on the nature of the Baylor Put/Call Agreement, Baylor’s minority interest in USPI was classified as a redeemable noncontrolling interest in our consolidated balance sheet. In June 2022, we entered into an agreement with Baylor (the “Share Purchase Agreement”) to purchase all of the Baylor Shares. Under the terms of the Share Purchase Agreement, we agreed to pay Baylor $406 million to buy its entire 5% voting ownership interest in USPI. We paid $11 million upon execution of the Share Purchase Agreement and are obligated to make a total of 35 additional non-interest bearing monthly payments of approximately $11 million, which payments commenced in August 2022. In June 2022, we recorded the present value of the purchase price as a liability on our balance sheet, with an offset to redeemable noncontrolling interest of $365 million for the carrying amount of the shares and $23 million to additional paid‑in capital for the difference between the carrying value and present value of the purchase price for the shares. At March 31, 2023, we had liabilities of $135 million recorded in other current liabilities and $159 million in other long-term liabilities in the accompanying Condensed Consolidated Balance Sheet for the purchase of these shares. The following table presents the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries: Three Months Ended March 31, 2023 2022 Balances at beginning of period $ 2,149 $ 2,203 Net income 79 94 Distributions paid to noncontrolling interests (73) (64) Accretion of redeemable noncontrolling interests — 95 Purchases and sales of businesses and noncontrolling interests, net 70 30 Balances at end of period $ 2,225 $ 2,358 The following tables present the composition by segment of our redeemable noncontrolling interests balances, as well as our net income available to redeemable noncontrolling interests: March 31, 2023 December 31, 2022 Hospital Operations $ 230 $ 233 Ambulatory Care 1,414 1,357 Conifer 581 559 Redeemable noncontrolling interests $ 2,225 $ 2,149 Three Months Ended March 31, 2023 2022 Hospital Operations $ — $ 22 Ambulatory Care 57 56 Conifer 22 16 Net income available to redeemable noncontrolling interests $ 79 $ 94

INCOME TAXES

INCOME TAXES	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
INCOME TAXES	INCOME TAXES During the three months ended March 31, 2023, we recorded income tax expense of $84 million in on pre-tax income of $380 million compared to $99 million on pre-tax income of $378 million during the three months ended March 31, 2022. Our provision for income taxes during interim reporting periods is calculated by applying an estimate of the annual effective tax rate to “ordinary” income or loss (pre-tax income or loss excluding unusual or infrequently occurring discrete items) for the reporting period. In calculating “ordinary” income, non‑taxable income or loss attributable to noncontrolling interests was deducted from pre-tax income. A reconciliation between the amount of reported income tax expense and the amount computed by multiplying income before income taxes by the statutory federal tax rate is presented below: Three Months Ended March 31, 2023 2022 Tax expense at statutory federal rate of 21% $ 80 $ 79 State income taxes, net of federal income tax benefit 16 14 Tax benefit attributable to noncontrolling interests (32) (29) Stock-based compensation tax benefit (2) (2) Changes in valuation allowance 19 32 Other items 3 5 Income tax expense $ 84 $ 99 During the three months ended March 31, 2023 and 2022, we recorded income tax expense of $19 million and $32 million, respectively, to increase the valuation allowance for interest expense carryforwards as a result of the limitation on business interest expense. The Inflation Reduction Act of 2022 implemented a corporate alternative minimum tax (“CAMT”) of 15% on book income of certain large corporations effective for tax years beginning after December 31, 2022. We expect to be subject to the CAMT, however, we currently do not expect any material impact on our consolidated statement of operations. There were no adjustments to our estimated liabilities for uncertain tax positions during the three months ended March 31, 2023. The total amount of unrecognized tax benefits as of March 31, 2023 was $34 million, of which $32 million, if recognized, would affect our effective tax rate and income tax expense from continuing operations. Our practice is to recognize interest and penalties related to income tax matters in income tax expense in our condensed consolidated statements of operations. No interest or penalties related to accrued liabilities for uncertain tax positions are included for the three months ended March 31, 2023. Total accrued interest and penalties on unrecognized tax benefits at March 31, 2023 were $1 million. As of March 31, 2023, no significant changes in unrecognized federal and state tax benefits were expected in the next 12 months as a result of the settlement of audits, the filing of amended tax returns or the expiration of statutes of limitations.

EARNINGS PER COMMON SHARE

EARNINGS PER COMMON SHARE	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
EARNINGS PER COMMON SHARE	EARNINGS PER COMMON SHARE The following table provides a reconciliation of the numerators and denominators of our basic and diluted earnings per common share calculations for our continuing operations. Net income available to our common shareholders is expressed in millions and weighted average shares are expressed in thousands. Net Income Available to Common Shareholders (Numerator) Weighted Per-Share Amount Three Months Ended March 31, 2023 Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share $ 143 102,289 $ 1.40 Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock (3) 3,717 (0.08) Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share $ 140 106,006 $ 1.32 Three Months Ended March 31, 2022 Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share $ 139 107,483 $ 1.29 Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock 3 4,537 (0.02) Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share $ 142 112,020 $ 1.27 During the three months ended March 31, 2023, our convertible instruments consisted of an agreement related to the ownership interest in a Hospital Operations segment joint venture and RSUs issued under the USPI Management Equity Plan. During the same period in 2022, our convertible instruments consisted of the aforementioned joint venture agreement, RSUs issued under the USPI Management Equity Plan and the Baylor Put/Call Agreement. Additional information about the USPI Management Equity Plan and the Baylor Put/Call Agreement is included in Notes 8 and 13, respectively.

FAIR VALUE MEASUREMENTS

FAIR VALUE MEASUREMENTS	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
FAIR VALUE MEASUREMENTS	FAIR VALUE MEASUREMENTS We are required to provide additional disclosures about fair value measurements as part of our financial statements for each major category of assets and liabilities measured at fair value. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities, which generally are not applicable to non‑financial assets and liabilities. Fair values determined by Level 2 inputs utilize data points that are observable, such as definitive sales agreements, appraisals or established market values of comparable assets. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability and include situations where there is little, if any, market activity for the asset or liability, such as internal estimates of future cash flows. Non-Recurring Fair Value Measurements The following table presents information about assets measured at fair value on a non-recurring basis and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair values: Total Quoted Prices Significant Other Significant At March 31, 2023: Long-lived assets held for sale $ 142 $ — $ 142 $ — At December 31, 2022: Long-lived assets held and used $ 167 $ — $ 167 $ — Financial Instruments The fair value of our long‑term debt (except for borrowings under the Credit Agreement) is based on quoted market prices (Level 1). The inputs used to establish the fair value of the borrowings outstanding under the Credit Agreement are considered to be Level 2 inputs. At March 31, 2023 and December 31, 2022, the estimated fair value of our long‑term debt was approximately 95.8% and 92.8%, respectively, of the carrying value of the debt.

ACQUISITIONS

ACQUISITIONS	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
ACQUISITIONS	ACQUISITIONS Preliminary purchase price allocations (representing the fair value of the consideration conveyed) for all acquisitions made during the three months ended March 31, 2023 and 2022 are as follows: Three Months Ended March 31, 2023 2022 Current assets $ 6 $ 3 Property and equipment 4 10 Other intangible assets 2 2 Goodwill 165 84 Other long-term assets 4 11 Previously held investments in unconsolidated affiliates (37) (18) Current liabilities (5) (5) Long-term liabilities (8) (19) Redeemable noncontrolling interests in equity of consolidated subsidiaries (56) (28) Noncontrolling interests (14) — Cash paid, net of cash acquired (48) (40) Gains on consolidations $ 13 $ — The goodwill generated from these transactions, the majority of which will be deductible for income tax purposes, can be attributed to the benefits that we expect to realize from operating efficiencies and growth strategies. The goodwill total of $165 million from acquisitions completed during the three months ended March 31, 2023 was recorded in our Ambulatory Care segment. Approximately $2 million and $3 million in transaction costs related to prospective and closed acquisitions were expensed during the three‑month periods ended March 31, 2023 and 2022, respectively, and were included in impairment and restructuring charges, and acquisition‑related costs in the accompanying Condensed Consolidated Statements of Operations. We are required to allocate the purchase prices of acquired businesses to assets acquired or liabilities assumed and, if applicable, noncontrolling interests based on their fair values. The excess of the purchase price allocated over those fair values is recorded as goodwill. The purchase price allocations for certain acquisitions completed in 2023 and 2022 are preliminary. We are in the process of assessing working capital balances, as well as obtaining and evaluating valuations of the acquired property and equipment, management contracts and other intangible assets, and noncontrolling interests. Therefore, those purchase price allocations, including goodwill, recorded in the accompanying Condensed Consolidated Financial Statements are subject to adjustment once the assessments and valuation work are completed and evaluated. Such adjustments will be recorded as soon as practical and within the measurement period as defined by the accounting literature.

SEGMENT INFORMATION

SEGMENT INFORMATION	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
SEGMENT INFORMATION	SEGMENT INFORMATION Our business consists of our Hospital Operations segment, our Ambulatory Care segment and our Conifer segment. The factors for determining the reportable segments include the manner in which management evaluates operating performance combined with the nature of the individual business activities. Our Hospital Operations segment is comprised of our acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro‑hospitals and physician practices. At March 31, 2023, our subsidiaries operated 61 hospitals serving primarily urban and suburban communities in nine states, including the new acute care hospital we opened in September 2022 in South Carolina. Our Ambulatory Care segment is comprised of the operations of USPI. At March 31, 2023, USPI had ownership interests in 445 ambulatory surgery centers (305 consolidated) and 24 surgical hospitals (eight consolidated) in 35 states. Effective June 30, 2022, we purchased all of the shares previously held by Baylor in USPI for $406 million, which increased our ownership interest in USPI’s voting shares from 95% to 100%. See Note 13 for additional information about this transaction. Our Conifer segment provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. At March 31, 2023, Conifer provided services to approximately 665 Tenet and non‑Tenet hospitals and other clients nationwide. Conifer provides revenue management, administrative support and various other services to Tenet hospitals. We believe the pricing terms for these services are commercially reasonable and consistent with estimated third‑party terms. At March 31, 2023, we owned approximately 76% of Conifer Health Solutions, LLC, which is Conifer’s principal subsidiary. The following tables include amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations, as applicable: March 31, 2023 December 31, 2022 Assets: Hospital Operations $ 15,397 $ 15,682 Ambulatory Care 10,733 10,557 Conifer 937 917 Total $ 27,067 $ 27,156 Three Months Ended March 31, 2023 2022 Capital expenditures: Hospital Operations $ 215 $ 132 Ambulatory Care 18 21 Conifer 2 2 Total $ 235 $ 155 Net operating revenues: Hospital Operations total prior to inter-segment eliminations $ 3,899 $ 3,798 Ambulatory Care 905 738 Conifer Tenet 107 115 Other clients 217 209 Total Conifer revenues 324 324 Inter-segment eliminations (107) (115) Total $ 5,021 $ 4,745 Equity in earnings of unconsolidated affiliates: Hospital Operations $ 3 $ 4 Ambulatory Care 47 42 Total $ 50 $ 46

BASIS OF PRESENTATION (Policies

BASIS OF PRESENTATION (Policies)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Description of Business and Basis of Presentation	Tenet Healthcare Corporation (together with our subsidiaries, referred to herein as “Tenet,” “we” or “us”) is a diversified healthcare services company headquartered in Dallas, Texas. Our care delivery network includes our subsidiary USPI Holding Company, Inc. (“USPI”), which had indirect ownership interests in 445 ambulatory surgery centers and 24 surgical hospitals at March 31, 2023. We hold noncontrolling interests in 156 of these facilities, which are recorded using the equity method of accounting. We also operated 61 acute care and specialty hospitals, 109 other outpatient facilities, a network of employed physicians and a Global Business Center (“GBC”) in Manila, Philippines at March 31, 2023. In addition, we operate Conifer Health Solutions, LLC, in which we own an interest of approximately 76%, through our Conifer Holdings, Inc. subsidiary (“Conifer”). Effective June 30, 2022, we purchased all of the shares previously held by Baylor University Medical Center (“Baylor”) in USPI for $406 million, which increased our ownership interest in USPI’s voting shares from 95% to 100%. See Note 13 for additional information about this transaction. Our business consists of our Hospital Operations and other (“Hospital Operations”) segment, our Ambulatory Care segment and our Conifer segment. Our Hospital Operations segment is comprised of our acute care and specialty hospitals, imaging centers, ancillary outpatient facilities, micro‑hospitals and physician practices. Our Ambulatory Care segment is comprised of the operations of USPI, which holds indirect ownership interests in and manages ambulatory surgery centers and surgical hospitals. Our Conifer segment provides revenue cycle management and value-based care services to hospitals, health systems, physician practices, employers and other clients. Almost all of the services comprising the operations of our Conifer segment are provided by Conifer Health Solutions, LLC or by one of its direct or indirect wholly owned subsidiaries. This quarterly report supplements our Annual Report on Form 10‑K for the year ended December 31, 2022 (“Annual Report”). As permitted by the Securities and Exchange Commission for interim reporting, we have omitted certain notes and disclosures that substantially duplicate those in our Annual Report. For further information, refer to the audited Consolidated Financial Statements and notes included in our Annual Report. Unless otherwise indicated, all dollar amounts presented in our Condensed Consolidated Financial Statements and these accompanying notes are expressed in millions (except per‑share amounts). We adopted the Financial Accounting Standards Board’s Accounting Standards Update (“ASU”) 2020-06, “Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity” (“ASU 2020-06”), effective as of January 1, 2022 using the modified retrospective method. Among other amendments, ASU 2020-06 changed the accounting for diluted earnings‑per‑share for convertible instruments and contracts that may be settled in cash or stock. ASU 2020-06 eliminated an entity’s ability to rebut the presumption of share settlement for convertible instruments and contracts that can be partially or fully settled in cash at the issuer’s election. Additionally, ASU 2020-06 requires that the if‑converted method, which is more dilutive than the treasury stock method, be used for all convertible instruments. As a result of our adoption of ASU 2020-06, diluted weighted average shares outstanding increased by approximately three million shares for both of the three-month periods ended March 31, 2023 and 2022, and diluted earnings per share available to Tenet common shareholders decreased by $0.07 and $0.01, respectively. Certain prior‑year amounts have been reclassified to conform to the current‑year presentation. Contract liabilities – long‑term are no longer significant enough to present separately. These obligations are now included in other long‑term liabilities in the accompanying Condensed Consolidated Balance Sheets. Although our Condensed Consolidated Financial Statements and these related notes are unaudited, we believe all adjustments considered necessary for a fair presentation have been included and are of a normal recurring nature. The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America (“GAAP”) requires us to make estimates and assumptions that affect the amounts reported in our Condensed Consolidated Financial Statements and these accompanying notes. We regularly evaluate the accounting policies and estimates we use. In general, we base the estimates on historical experience and on assumptions that we believe to be reasonable given the particular circumstances in which we operate. Actual results may vary from those estimates. The financial and statistical information we report to other regulatory agencies may be prepared on a basis other than GAAP or using different assumptions or reporting periods and, therefore, may vary from the amounts presented herein. Although we make every effort to ensure that the information we report to those agencies is accurate, complete and consistent with applicable reporting guidelines, we cannot be responsible for the accuracy of the information they make available to the public. Operating results for the three‑month period ended March 31, 2023 are not necessarily indicative of the results that may be expected for the full year. Reasons for this include, but are not limited to: the impact of the COVID‑19 pandemic on our operations, business, financial condition and cash flows; the impact of the demand for, and availability of, qualified medical personnel on compensation costs; the impact of cybersecurity incidents on our operations; overall revenue and cost trends, particularly the timing and magnitude of price changes; fluctuations in contractual allowances and cost report settlements and valuation allowances; managed care contract negotiations, settlements or terminations and payer consolidations; trends in patient accounts receivable collectability and associated implicit price concessions; fluctuations in interest rates; levels of malpractice insurance expense and settlement trends; impairment of long‑lived assets and goodwill; restructuring charges; losses, costs and insurance recoveries related to cybersecurity incidents, natural disasters and weather‑related occurrences; litigation and investigation costs; acquisitions and dispositions of facilities and other assets; gains (losses) on sales, consolidation and deconsolidation of facilities; income tax rates and deferred tax asset valuation allowance activity; changes in estimates of accruals for annual incentive compensation; the timing and amounts of stock option and restricted stock unit grants to employees and directors; gains (losses) from early extinguishment of debt; and changes in occupancy levels and patient volumes. Our hospitals and outpatient facilities are subject to various factors that affect our service mix, revenue mix and patient volumes and, thereby, impact our net patient service revenues and results of operations. These factors include, among others: changes in federal, state and local healthcare and business regulations; changes in general economic conditions nationally and regionally, including inflation and the impacts of the COVID-19 pandemic and other factors on business conditions, the economy and financial markets; the number of uninsured and underinsured individuals in local communities treated at our facilities; disease hotspots and seasonal cycles of illness; climate and weather conditions; physician recruitment, satisfaction, retention and attrition; advances in technology and treatments that reduce length of stay or permit procedures to be performed in an outpatient rather than inpatient setting; local healthcare competitors; utilization pressure by managed care organizations, as well as managed care contract negotiations or terminations; performance data on quality measures and patient satisfaction, as well as standard charges for services; any unfavorable publicity about us, or our joint venture partners, that impacts our relationships with physicians and patients; and changing consumer behavior, including with respect to the timing of elective procedures. These considerations apply to year‑to‑year comparisons as well.
Cash and Cash Equivalents	We treat highly liquid investments with original maturities of three months or less as cash equivalents. Cash and cash equivalents were $766 million and $858 million at March 31, 2023 and December 31, 2022, respectively. At March 31, 2023 and December 31, 2022, our book overdrafts were $139 million and $266 million, respectively, which were classified as accounts payable. At March 31, 2023 and December 31, 2022, $122 million and $140 million, respectively, of total cash and cash equivalents in the accompanying Condensed Consolidated Balance Sheets were intended for the operations of our insurance‑related subsidiaries. Also at March 31, 2023 and December 31, 2022, we had $63 million and $196 million, respectively, of property and equipment purchases accrued for items received but not yet paid. Of these amounts, $57 million and $191 million, respectively, were included in accounts payable.
Investments in Unconsolidated Affiliates	controlled 313 of the facilities within our Ambulatory Care segment and, therefore, consolidate their results. We account for many of the facilities our Ambulatory Care segment holds ownership interests in (156 of 469), as well as additional companies in which our Hospital Operations segment holds ownership interests, under the equity method as investments in unconsolidated affiliates and report only our share of net income as equity in earnings of unconsolidated affiliates in our condensed consolidated statements of operations.

BASIS OF PRESENTATION (Tables)

BASIS OF PRESENTATION (Tables)	3 Months Ended
	Mar. 31, 2023
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Schedule of Grant Funds	The table below summarizes grant income recognized by our Hospital Operations and Ambulatory Care segments, which is presented in grant income in our condensed consolidated statements of operations: Three Months Ended March 31, 2023 2022 Grant income recognized from COVID-19 relief programs: Included in grant income: Hospital Operations $ 3 $ 4 Ambulatory Care — 2 $ 3 $ 6
Schedule of Other Intangible Assets	The following table provides information regarding other intangible assets, which were included in the accompanying Condensed Consolidated Balance Sheets: Gross Accumulated Net Book Value At March 31, 2023: Other intangible assets with finite useful lives: Capitalized software costs $ 1,759 $ (1,202) $ 557 Contracts 294 (150) 144 Other 92 (77) 15 Total other intangible assets with finite lives 2,145 (1,429) 716 Other intangible assets with indefinite useful lives: Trade names 105 — 105 Contracts 605 — 605 Other 6 — 6 Total other intangible assets with indefinite lives 716 — 716 Total other intangible assets $ 2,861 $ (1,429) $ 1,432 At December 31, 2022: Other intangible assets with finite useful lives: Capitalized software costs $ 1,751 $ (1,206) $ 545 Contracts 295 (146) 149 Other 92 (76) 16 Total other intangible assets with finite lives 2,138 (1,428) 710 Other intangible assets with indefinite useful lives: Trade names 105 — 105 Contracts 603 — 603 Other 6 — 6 Total other intangible assets with indefinite lives 714 — 714 Total other intangible assets $ 2,852 $ (1,428) $ 1,424
Schedule of Indefinite-Lived Intangible Assets	The following table provides information regarding other intangible assets, which were included in the accompanying Condensed Consolidated Balance Sheets: Gross Accumulated Net Book Value At March 31, 2023: Other intangible assets with finite useful lives: Capitalized software costs $ 1,759 $ (1,202) $ 557 Contracts 294 (150) 144 Other 92 (77) 15 Total other intangible assets with finite lives 2,145 (1,429) 716 Other intangible assets with indefinite useful lives: Trade names 105 — 105 Contracts 605 — 605 Other 6 — 6 Total other intangible assets with indefinite lives 716 — 716 Total other intangible assets $ 2,861 $ (1,429) $ 1,432 At December 31, 2022: Other intangible assets with finite useful lives: Capitalized software costs $ 1,751 $ (1,206) $ 545 Contracts 295 (146) 149 Other 92 (76) 16 Total other intangible assets with finite lives 2,138 (1,428) 710 Other intangible assets with indefinite useful lives: Trade names 105 — 105 Contracts 603 — 603 Other 6 — 6 Total other intangible assets with indefinite lives 714 — 714 Total other intangible assets $ 2,852 $ (1,428) $ 1,424
Schedule of Estimated Future Amortization of Intangibles with Finite Useful Lives	Estimated future amortization of intangibles with finite useful lives at March 31, 2023 was as follows: Nine Months Ending Years Ending Later Years December 31, Total 2023 2024 2025 2026 2027 Amortization of intangible assets $ 716 $ 124 $ 123 $ 101 $ 88 $ 71 $ 209
Schedule of Other Current Assets	The principal components of other current assets in the accompanying Condensed Consolidated Balance Sheets were as follows: March 31, 2023 December 31, 2022 Prepaid expenses $ 380 $ 400 Contract assets 202 200 California provider fee program receivables 311 367 Receivables from other government programs 152 187 Guarantees 187 143 Non-patient receivables 354 390 Other 85 88 Total other current assets $ 1,671 $ 1,775
Schedule of Equity Method Investments	Summarized financial information for these equity method investees is included in the following table. For investments acquired during the reported periods, amounts in the table include 100% of the investee’s results beginning on the date of our acquisition of the investment. Three Months Ended March 31, 2023 2022 Net operating revenues $ 783 $ 769 Net income $ 185 $ 169 Net income available to the investees $ 107 $ 98

ACCOUNTS RECEIVABLE (Tables)

ACCOUNTS RECEIVABLE (Tables)	3 Months Ended
	Mar. 31, 2023
Accounts Receivable Additional Disclosures [Abstract]
Schedule of Components of Accounts Receivable	The principal components of accounts receivable are presented in the table below: March 31, 2023 December 31, 2022 Patient accounts receivable $ 2,689 $ 2,746 Estimated future recoveries 150 149 Cost report settlements receivable, net of payables and valuation allowances 44 48 Accounts receivable, net $ 2,883 $ 2,943
Schedule of Location of Assets and Liabilities	The following table summarizes the amount and classification of assets and liabilities in the accompanying Condensed Consolidated Balance Sheets related to California’s provider fee program: March 31, 2023 December 31, 2022 Assets: Other current assets $ 311 $ 367 Investments and other assets $ 261 $ 197 Liabilities: Other current liabilities $ 146 $ 145 Other long-term liabilities $ 55 $ 63
Schedule of Estimated Costs for Charity Care and Self-Pay Patients	The following table presents our estimated costs (based on selected operating expenses, which include salaries, wages and benefits, supplies and other operating expenses) of caring for our uninsured and charity patients: Three Months Ended March 31, 2023 2022 Estimated costs for: Uninsured patients $ 123 $ 122 Charity care patients 24 21 Total $ 147 $ 143

CONTRACT BALANCES (Tables)

CONTRACT BALANCES (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Schedule Of Opening And Closing Balances Of Company's Contract Assets	The opening and closing balances of contract assets and contract liabilities, as well as their classification in our condensed consolidated balance sheets, for our Hospital Operations segment were as follows: Contract Assets Contract Liabilities – Current Advances from Medicare December 31, 2022 $ 185 $ — March 31, 2023 185 — Increase $ — $ — December 31, 2021 $ 181 $ 876 March 31, 2022 169 682 Decrease $ (12) $ (194) The opening and closing balances of Conifer’s receivables, contract assets, and current and long‑term contract liabilities were as follows: Receivables Contract Assets – Unbilled Revenue Contract Liabilities – Current Contract Liabilities – Long-Term December 31, 2022 $ 37 $ 15 $ 110 $ 13 March 31, 2023 57 17 76 13 Increase (decrease) $ 20 $ 2 $ (34) $ — December 31, 2021 $ 28 $ 18 $ 79 $ 15 March 31, 2022 34 15 90 14 Increase (decrease) $ 6 $ (3) $ 11 $ (1)

ASSETS AND LIABILITIES HELD F_2

ASSETS AND LIABILITIES HELD FOR SALE (Tables)	3 Months Ended
	Mar. 31, 2023
Discontinued Operation, Additional Disclosures [Abstract]
Schedule of Assets and Liabilities Classified As Held for Sale	Assets and liabilities classified as held for sale were comprised of the following: March 31, 2023 Accounts receivable $ 28 Other current assets 11 Investments and other long-term assets 3 Property and equipment 63 Other intangible assets 6 Goodwill 31 Current liabilities (22) Long-term liabilities (1) Net assets held for sale $ 119

LONG-TERM DEBT (Tables)

LONG-TERM DEBT (Tables)	3 Months Ended
	Mar. 31, 2023
Long-Term Debt and Lease Obligation [Abstract]
Schedule of Long-Term Debt	The table below presents our long‑term debt included in the accompanying Condensed Consolidated Balance Sheets: March 31, 2023 December 31, 2022 Senior unsecured notes: 6.125% due 2028 $ 2,500 $ 2,500 6.875% due 2031 362 362 Senior secured first lien notes: 4.625% due July 2024 756 756 4.625% due September 2024 589 589 4.875% due 2026 2,100 2,100 5.125% due 2027 1,500 1,500 4.625% due 2028 600 600 4.250% due 2029 1,400 1,400 4.375% due 2030 1,450 1,450 6.125% due 2030 2,000 2,000 Senior secured second lien notes: 6.250% due 2027 1,500 1,500 Finance leases, mortgages and other notes 451 453 Unamortized issue costs and note discounts (125) (131) Total long-term debt 15,083 15,079 Less: Current portion 148 145 Long-term debt, net of current portion $ 14,935 $ 14,934

EMPLOYEE BENEFIT PLANS (Tables)

EMPLOYEE BENEFIT PLANS (Tables)	3 Months Ended
	Mar. 31, 2023
Share-Based Payment Arrangement [Abstract]
Schedule of Information About Stock Options by Range of Exercise Prices	The following table summarizes information about our outstanding stock options at March 31, 2023: Options Outstanding and Exercisable Range of Exercise Prices Number of Weighted Average Weighted Average $18.99 to $20.609 293,796 4.4 years $ 19.75 $20.61 to $35.430 167,151 5.8 years $ 29.62 460,947 4.9 years $ 23.33
Schedule of Restricted Stock Unit Activity	The following table summarizes activity with respect to restricted stock units (“RSUs”) during the three months ended March 31, 2023: Number of RSUs Weighted Average Grant Unvested at December 31, 2022 1,520,418 $ 66.36 Granted 678,748 $ 62.45 Performance-based adjustment 185,901 $ 48.97 Vested (823,418) $ 52.95 Forfeited (26,660) $ 56.31 Unvested at March 31, 2023 1,534,989 $ 65.58 The following table summarizes RSU activity under the USPI Management Equity Plan during the three months ended March 31, 2023: Number of RSUs Weighted Average Grant Unvested at December 31, 2022 922,840 $ 34.13 Vested (303,171) $ 34.13 Unvested at March 31, 2023 619,669 $ 34.13
Schedule of Share-based Payment Award, Awards Other Than Options, Valuation Assumptions	Significant inputs used in our valuation of these RSUs included the following: Three Months Ended March 31, 2023 2022 Expected volatility 53.6% - 65.6% 39.6% - 68.1% Risk-free interest rate 4.5% - 4.8% 1.0% - 1.7%

EQUITY (Tables)

EQUITY (Tables)	3 Months Ended
	Mar. 31, 2023
Stockholders' Equity Note [Abstract]
Schedule of Changes In Consolidated Equity	The following tables present the changes in consolidated equity (dollars in millions, share amounts in thousands): Common Stock Additional Accumulated Accumulated Treasury Noncontrolling Total Equity Shares Issued Par Balances at December 31, 2022 102,247 $ 8 $ 4,778 $ (181) $ (803) $ (2,660) $ 1,317 $ 2,459 Net income — — — — 143 — 74 217 Distributions paid to noncontrolling interests — — — — — — (61) (61) Other comprehensive income — — — 2 — — — 2 Purchases of businesses and noncontrolling interests, net — — 2 — — — 17 19 Repurchases of common stock (906) — — — — (50) — (50) Stock-based compensation expense and issuance of common stock 571 — (6) — — — — (6) Balances at March 31, 2023 101,912 $ 8 $ 4,774 $ (179) $ (660) $ (2,710) $ 1,347 $ 2,580 Common Stock Additional Accumulated Accumulated Treasury Noncontrolling Total Equity Shares Issued Par Balances at December 31, 2021 107,189 $ 8 $ 4,877 $ (233) $ (1,214) $ (2,410) $ 1,026 $ 2,054 Net income — — — — 140 — 46 186 Distributions paid to noncontrolling interests — — — — — — (71) (71) Accretion of redeemable noncontrolling interests — — (95) — — — — (95) Sales of businesses and noncontrolling interests, net — — (7) — — — (1) (8) Stock-based compensation expense and issuance of common stock 499 — (10) — — — — (10) Balances at March 31, 2022 107,688 $ 8 $ 4,765 $ (233) $ (1,074) $ (2,410) $ 1,000 $ 2,056
Schedule of Share Repurchase Activity	The table below summarizes transactions completed under the repurchase program during the three months ended March 31, 2023: Period Total Number of Shares Purchased Average Price Paid per Share Total Number of Shares Purchased as Part of Publicly Announced Program Maximum Dollar Value of Shares That May Yet be Purchased Under the Program (In Thousands) (In Thousands) (In Millions) January 1 through January 31, 2023 — $ — — $ 750 February 1 through February 28, 2023 — $ — — $ 750 March 1 through March 31, 2023 906 $ 55.03 906 $ 700

NET OPERATING REVENUES (Tables)

NET OPERATING REVENUES (Tables)	3 Months Ended
	Mar. 31, 2023
Revenue from Contract with Customer [Abstract]
Schedule of Disaggregation of Operating Revenues Less Provision for Doubtful Accounts and Implicit Price Concessions	The table below presents our sources of net operating revenues: Three Months Ended March 31, 2023 2022 Hospital Operations: Net patient service revenues from hospitals and related outpatient facilities: Medicare $ 613 $ 619 Medicaid 280 249 Managed care (1) 2,503 2,438 Uninsured 31 38 Indemnity and other 140 164 Total 3,567 3,508 Other revenues (2) 332 290 Hospital Operations total prior to inter-segment eliminations 3,899 3,798 Ambulatory Care 905 738 Conifer 324 324 Inter-segment eliminations (107) (115) Net operating revenues $ 5,021 $ 4,745 (1) Includes Medicare and Medicaid managed care programs. (2) Primarily physician practices revenues. The following tables present the composition of net operating revenues for our Ambulatory Care and Conifer segments: Three Months Ended March 31, 2023 2022 Ambulatory Care: Net patient service revenues $ 868 $ 704 Management fees 30 29 Revenue from other sources 7 5 Ambulatory Care net operating revenues $ 905 $ 738 Three Months Ended March 31, 2023 2022 Conifer: Revenue cycle services – Tenet $ 104 $ 112 Revenue cycle services – other clients 199 189 Other services – Tenet 3 3 Other services – other clients 18 20 Conifer net operating revenues $ 324 $ 324
Schedule of Performance Obligation, Expected Timing of Satisfaction	The following table includes Conifer’s revenue that is expected to be recognized in the future related to performance obligations that are unsatisfied, or partially unsatisfied, at the end of the reporting period: Nine Months Ending Years Ending Later Years December 31, Total 2023 2024 2025 2026 2027 Performance obligations $ 5,926 $ 500 $ 603 $ 603 $ 603 $ 603 $ 3,014

CLAIMS AND LAWSUITS (Tables)

CLAIMS AND LAWSUITS (Tables)	3 Months Ended
	Mar. 31, 2023
Commitments and Contingencies Disclosure [Abstract]
Schedule of Reconciliations of Legal Settlements and Related Costs	The following table presents reconciliations of the beginning and ending liability balances in connection with legal settlements and related costs: Balances at Litigation and Cash Other Balances at Three Months Ended March 31, 2023 $ 51 $ 4 $ (5) $ — $ 50 Three Months Ended March 31, 2022 $ 78 $ 20 $ (36) $ 2 $ 64

REDEEMABLE NONCONTROLLING INT_2

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES (Tables)	3 Months Ended
	Mar. 31, 2023
Noncontrolling Interest [Abstract]
Schedule of Changes in Redeemable Noncontrolling Interests in Equity of Consolidated Subsidiaries	The following table presents the changes in redeemable noncontrolling interests in equity of consolidated subsidiaries: Three Months Ended March 31, 2023 2022 Balances at beginning of period $ 2,149 $ 2,203 Net income 79 94 Distributions paid to noncontrolling interests (73) (64) Accretion of redeemable noncontrolling interests — 95 Purchases and sales of businesses and noncontrolling interests, net 70 30 Balances at end of period $ 2,225 $ 2,358 The following tables present the composition by segment of our redeemable noncontrolling interests balances, as well as our net income available to redeemable noncontrolling interests: March 31, 2023 December 31, 2022 Hospital Operations $ 230 $ 233 Ambulatory Care 1,414 1,357 Conifer 581 559 Redeemable noncontrolling interests $ 2,225 $ 2,149 Three Months Ended March 31, 2023 2022 Hospital Operations $ — $ 22 Ambulatory Care 57 56 Conifer 22 16 Net income available to redeemable noncontrolling interests $ 79 $ 94

INCOME TAXES (Tables)

INCOME TAXES (Tables)	3 Months Ended
	Mar. 31, 2023
Income Tax Disclosure [Abstract]
Schedule of Reconciliation Between Reported Income Tax Expense and Income Taxes Calculated by the Statutory Federal Income Tax Rate	A reconciliation between the amount of reported income tax expense and the amount computed by multiplying income before income taxes by the statutory federal tax rate is presented below: Three Months Ended March 31, 2023 2022 Tax expense at statutory federal rate of 21% $ 80 $ 79 State income taxes, net of federal income tax benefit 16 14 Tax benefit attributable to noncontrolling interests (32) (29) Stock-based compensation tax benefit (2) (2) Changes in valuation allowance 19 32 Other items 3 5 Income tax expense $ 84 $ 99

EARNINGS PER COMMON SHARE (Tabl

EARNINGS PER COMMON SHARE (Tables)	3 Months Ended
	Mar. 31, 2023
Earnings Per Share [Abstract]
Schedule of Reconcile of Numerators and Denominators of Our Basic and Diluted Earnings Per Common Share	The following table provides a reconciliation of the numerators and denominators of our basic and diluted earnings per common share calculations for our continuing operations. Net income available to our common shareholders is expressed in millions and weighted average shares are expressed in thousands. Net Income Available to Common Shareholders (Numerator) Weighted Per-Share Amount Three Months Ended March 31, 2023 Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share $ 143 102,289 $ 1.40 Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock (3) 3,717 (0.08) Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share $ 140 106,006 $ 1.32 Three Months Ended March 31, 2022 Net income available to Tenet Healthcare Corporation common shareholders for basic earnings per share $ 139 107,483 $ 1.29 Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock 3 4,537 (0.02) Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share $ 142 112,020 $ 1.27

FAIR VALUE MEASUREMENTS (Tables

FAIR VALUE MEASUREMENTS (Tables)	3 Months Ended
	Mar. 31, 2023
Fair Value Disclosures [Abstract]
Schedule of Fair Value Assets on a Nonrecurring Basis	The following table presents information about assets measured at fair value on a non-recurring basis and indicates the fair value hierarchy of the valuation techniques we utilized to determine such fair values: Total Quoted Prices Significant Other Significant At March 31, 2023: Long-lived assets held for sale $ 142 $ — $ 142 $ — At December 31, 2022: Long-lived assets held and used $ 167 $ — $ 167 $ —

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	3 Months Ended
	Mar. 31, 2023
Business Combination and Asset Acquisition [Abstract]
Schedule of Preliminary Purchase Price Allocation	Preliminary purchase price allocations (representing the fair value of the consideration conveyed) for all acquisitions made during the three months ended March 31, 2023 and 2022 are as follows: Three Months Ended March 31, 2023 2022 Current assets $ 6 $ 3 Property and equipment 4 10 Other intangible assets 2 2 Goodwill 165 84 Other long-term assets 4 11 Previously held investments in unconsolidated affiliates (37) (18) Current liabilities (5) (5) Long-term liabilities (8) (19) Redeemable noncontrolling interests in equity of consolidated subsidiaries (56) (28) Noncontrolling interests (14) — Cash paid, net of cash acquired (48) (40) Gains on consolidations $ 13 $ —

SEGMENT INFORMATION (Tables)

SEGMENT INFORMATION (Tables)	3 Months Ended
	Mar. 31, 2023
Segment Reporting [Abstract]
Schedule of Reconciliation of Assets by Reportable Segment to Consolidated Assets	The following tables include amounts for each of our reportable segments and the reconciling items necessary to agree to amounts reported in the accompanying Condensed Consolidated Balance Sheets and Condensed Consolidated Statements of Operations, as applicable: March 31, 2023 December 31, 2022 Assets: Hospital Operations $ 15,397 $ 15,682 Ambulatory Care 10,733 10,557 Conifer 937 917 Total $ 27,067 $ 27,156
Schedule of Reconciliation of Other Significant Reconciling Items From Segments to Consolidated	Three Months Ended March 31, 2023 2022 Capital expenditures: Hospital Operations $ 215 $ 132 Ambulatory Care 18 21 Conifer 2 2 Total $ 235 $ 155 Net operating revenues: Hospital Operations total prior to inter-segment eliminations $ 3,899 $ 3,798 Ambulatory Care 905 738 Conifer Tenet 107 115 Other clients 217 209 Total Conifer revenues 324 324 Inter-segment eliminations (107) (115) Total $ 5,021 $ 4,745 Equity in earnings of unconsolidated affiliates: Hospital Operations $ 3 $ 4 Ambulatory Care 47 42 Total $ 50 $ 46

BASIS OF PRESENTATION - Descrip

BASIS OF PRESENTATION - Description of Business and Basis of Presentation (Details) $ / shares in Units, shares in Thousands, $ in Millions	1 Months Ended	3 Months Ended
	Jun. 30, 2022 USD ($)	Mar. 31, 2023 hospital healthcare_facility surgery_center $ / shares shares	Mar. 31, 2022 $ / shares shares	Jun. 29, 2022
Business Acquisition [Line Items]
Number of acute care and specialty hospitals operated		61
Increase in diluted weighted average shares outstanding (in shares) | shares		106,006	112,020
Change in earnings per share, diluted (in dollars per share) | $ / shares		$ 1.32	$ 1.28
Cumulative Effect, Period of Adoption, Adjustment | Accounting Standards Update 2020-06
Business Acquisition [Line Items]
Increase in diluted weighted average shares outstanding (in shares) | shares		3,000	3,000
Change in earnings per share, diluted (in dollars per share) | $ / shares		$ (0.07)	$ (0.01)
Ambulatory Care
Business Acquisition [Line Items]
Number of outpatient centers recorded using equity method		156
Hospital Operations
Business Acquisition [Line Items]
Number of outpatient facilities operated | healthcare_facility		109
United Surgical Partners International | Ambulatory Care
Business Acquisition [Line Items]
Ownership percentage by parent (percent)	100%			95%
Conifer Health Solutions, LLC
Business Acquisition [Line Items]
Ownership percentage by parent (percent)		76%
United Surgical Partners International | Ambulatory Care
Business Acquisition [Line Items]
Number of ambulatory surgery centers operated by subsidiaries, including indirect ownership | surgery_center		445
Number of surgical hospitals operated by subsidiaries		24
Number of outpatient centers recorded using equity method | healthcare_facility		156
Baylor University Medical Center | United Surgical Partners International
Business Acquisition [Line Items]
Share purchase agreement amount of payment | $	$ 406

BASIS OF PRESENTATION - COVID-1

BASIS OF PRESENTATION - COVID-19 Pandemic (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) segment	Mar. 31, 2022 USD ($)	Dec. 31, 2022 USD ($)
Business Acquisition [Line Items]
Number of reportable segments | segment	3
Received cash payments	$ 0
Grant income	3,000,000	$ 6,000,000
Deferred revenue	4,000,000		$ 7,000,000
Hospital Operations
Business Acquisition [Line Items]
Received cash payments		4,000,000
Grant income	3,000,000	4,000,000
Contract liabilities advance payments (less than $1 million)		194,000,000
Ambulatory Care
Business Acquisition [Line Items]
Received cash payments		1,000,000
Grant income	$ 0	2,000,000
Contract liabilities advance payments (less than $1 million)		$ 1,000,000

BASIS OF PRESENTATION - Leases

BASIS OF PRESENTATION - Leases (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Business Acquisition [Line Items]
Non-cancellable finance leases entered into	$ 19	$ 18
Non-cancellable operating leases liability entered into	$ 44	187
Hospital Operations
Business Acquisition [Line Items]
Net proceeds from sale of buildings		147
Gain on sale of properties		69
Operating lease, liability		103
Operating lease assets		$ 103

BASIS OF PRESENTATION - Cash an

BASIS OF PRESENTATION - Cash and Cash Equivalents (Details) - USD ($) $ in Millions	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Cash and Cash Equivalents
Cash and cash equivalents	$ 766	$ 858
Accrued property and equipment purchases for items received but not yet paid	63	196
Captive Insurance Subsidiaries
Cash and Cash Equivalents
Cash and cash equivalents	122	140
Accounts Payable
Cash and Cash Equivalents
Book overdrafts classified as accounts payable	139	266
Accrued property and equipment purchases for items received but not yet paid	$ 57	$ 191

BASIS OF PRESENTATION - Other I

BASIS OF PRESENTATION - Other Intangible Assets (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	$ 2,145	$ 2,138
Accumulated Amortization	(1,429)	(1,428)
Net Book Value	716	710
Total other intangible assets with indefinite lives	716	714
Gross Carrying Amount	2,861	2,852
Net Book Value	1,432	1,424
Trade names
Finite-Lived Intangible Assets [Line Items]
Total other intangible assets with indefinite lives	105	105
Contracts
Finite-Lived Intangible Assets [Line Items]
Total other intangible assets with indefinite lives	605	603
Other
Finite-Lived Intangible Assets [Line Items]
Total other intangible assets with indefinite lives	6	6
Capitalized software costs
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	1,759	1,751
Accumulated Amortization	(1,202)	(1,206)
Net Book Value	557	545
Contracts
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	294	295
Accumulated Amortization	(150)	(146)
Net Book Value	144	149
Other
Finite-Lived Intangible Assets [Line Items]
Gross Carrying Amount	92	92
Accumulated Amortization	(77)	(76)
Net Book Value	$ 15	$ 16

BASIS OF PRESENTATION - Amortiz

BASIS OF PRESENTATION - Amortization of Intangible Assets (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract]
Net Book Value	$ 716		$ 710
2023	124
2024	123
2025	101
2026	88
2027	71
Later Years	209
Amortization expense	$ 42	$ 29

BASIS OF PRESENTATION - Other C

BASIS OF PRESENTATION - Other Current Asset (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Accounts receivable and allowance for doubtful accounts
Prepaid expenses	$ 380	$ 400
Contract assets	202	200
California provider fee program receivables	2,883	2,943
Receivables from other government programs	152	187
Guarantees	187	143
Non-patient receivables	354	390
Other	85	88
Other current assets	1,671	1,775
California's Provider Fee Program
Accounts receivable and allowance for doubtful accounts
California provider fee program receivables	$ 311	$ 367

BASIS OF PRESENTATION - Investm

BASIS OF PRESENTATION - Investments in Unconsolidated Affiliates (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) hospital	Mar. 31, 2022 USD ($)
Schedule of Equity Method Investments [Line Items]
Grant income	$ 3	$ 6
Investee results reflected (percent)	1
Net operating revenues	$ 5,021	4,745
Net income	296	280
Equity Method Investment, Nonconsolidated Investee or Group of Investees
Schedule of Equity Method Investments [Line Items]
Net operating revenues	783	769
Net income	185	169
Net income available to the investees	$ 107	98
Ambulatory Care
Schedule of Equity Method Investments [Line Items]
Number of outpatient centers operated | hospital	313
Number of outpatient centers recorded using equity method | hospital	156
Number of outpatient centers | hospital	469
Grant income	$ 0	2
Net operating revenues	$ 905	$ 738

ACCOUNTS RECEIVABLE - Component

ACCOUNTS RECEIVABLE - Components (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Accounts receivable and allowance for doubtful accounts
Accounts receivable	$ 2,883	$ 2,943
Continuing operations:
Accounts receivable and allowance for doubtful accounts
Patient accounts receivable	2,689	2,746
Estimated future recoveries	150	149
Cost report settlements receivable, net of payables and valuation allowances	44	48
Accounts receivable	$ 2,883	$ 2,943

ACCOUNTS RECEIVABLE - Location

ACCOUNTS RECEIVABLE - Location of Assets and Liabilities (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Assets:
Other current assets	$ 2,883	$ 2,943
Liabilities:
Other current liabilities	1,192	1,504
California's Provider Fee Program
Assets:
Other current assets	311	367
California's Provider Fee Program | Other current assets
Assets:
Other current assets	311	367
California's Provider Fee Program | Investments and other assets
Assets:
Investments and other assets	261	197
California's Provider Fee Program | Other current liabilities
Liabilities:
Other current liabilities	146	145
California's Provider Fee Program | Other long-term liabilities
Liabilities:
Other long-term liabilities	$ 55	$ 63

ACCOUNTS RECEIVABLE - Allowance

ACCOUNTS RECEIVABLE - Allowance (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Accounts receivable and allowance for doubtful accounts
Estimated costs of caring	$ 147	$ 143
Uninsured patients
Accounts receivable and allowance for doubtful accounts
Estimated costs of caring	123	122
Charity care patients
Accounts receivable and allowance for doubtful accounts
Estimated costs of caring	$ 24	$ 21

CONTRACT BALANCES - Hospital Op

CONTRACT BALANCES - Hospital Operations and Ambulatory Care Segments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Percentage of contract assets that meet the conditions for unconditional right to payment (percentage)	88%		88%
Contract Assets
Balance at beginning of period	$ 200
Balance at end of period	202
Contract Liabilities – Current Advances from Medicare
Balance at beginning of period	110
Balance at end of period	76
Hospital Operations and Other
Contract Assets
Balance at beginning of period	185	$ 181
Balance at end of period	185	169
Increase (decrease)	0	(12)
Contract Liabilities – Current Advances from Medicare
Balance at beginning of period	0	876
Balance at end of period	0	682
Hospital Operations and Other | Short-term Contract with Customer
Contract Liabilities – Current Advances from Medicare
Increase (decrease)	$ 0	(194)
Hospital Operations
Contract Liabilities – Current Advances from Medicare
Contract liabilities advance payments (less than $1 million)		194
Ambulatory Care
Contract Liabilities – Current Advances from Medicare
Contract liabilities advance payments (less than $1 million)		$ 1

CONTRACT BALANCES - Conifer Seg

CONTRACT BALANCES - Conifer Segment (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Contract Assets – Unbilled Revenue
Balance at beginning of period	$ 200
Balance at end of period	202
Contract Liabilities – Current Deferred Revenue
Balance at beginning of period	110
Balance at end of period	76
Conifer
Receivables
Balance at beginning of period	37	$ 28
Balance at end of period	57	34
Increase (decrease)	20	6
Contract Assets – Unbilled Revenue
Balance at beginning of period	15	18
Balance at end of period	17	15
Increase (decrease)	2	(3)
Contract Liabilities – Current Deferred Revenue
Balance at beginning of period	110	79
Balance at end of period	76	90
Contract Liabilities – Long-Term Advances from Medicare
Balance at beginning of period	13	15
Balance at end of period	13	14
Amount of revenue recognized included in current deferred revenue liability	64	49
Conifer | Short-term Contract with Customer
Contract Liabilities – Current Deferred Revenue
Increase (decrease)	(34)	11
Contract Liabilities – Long-Term Advances from Medicare
Increase (decrease)	(34)	11
Conifer | Long-term Contract with Customer
Contract Liabilities – Current Deferred Revenue
Increase (decrease)	0	(1)
Contract Liabilities – Long-Term Advances from Medicare
Increase (decrease)	$ 0	$ (1)

CONTRACT BALANCES - Contract Co

CONTRACT BALANCES - Contract Costs (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Amortization expense	$ 1	$ 1
Unamortized contract cost	$ 24		$ 24

ASSETS AND LIABILITIES HELD F_3

ASSETS AND LIABILITIES HELD FOR SALE - Narrative (Details) - USD ($) $ in Millions	Mar. 31, 2023	Jan. 31, 2023	Dec. 31, 2022
Current Assets and Liabilities Held for Sale
Assets held for sale	$ 142		$ 0
Liabilities held for sale	23		$ 0
San Ramon RMC | Discontinued Operations, Held-for-sale
Current Assets and Liabilities Held for Sale
Liabilities held for sale	$ 22
San Ramon RMC | Discontinued Operations, Held-for-sale
Current Assets and Liabilities Held for Sale
Ownership percentage by parent (percent)		51%

ASSETS AND LIABILITIES HELD F_4

ASSETS AND LIABILITIES HELD FOR SALE - Schedule of Assets and Liabilities Held for Sale (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Current liabilities	$ (23)	$ 0
San Ramon RMC | Discontinued Operations, Held-for-sale
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Accounts receivable	28
Other current assets	11
Investments and other long-term assets	3
Property and equipment	63
Other intangible assets	6
Goodwill	31
Current liabilities	(22)
Long-term liabilities	(1)
Net assets held for sale	$ 119

IMPAIRMENT AND RESTRUCTURING _2

IMPAIRMENT AND RESTRUCTURING CHARGES, AND ACQUISITION-RELATED COSTS (Details) $ in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) segment	Mar. 31, 2022 USD ($)
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Number of reportable segments | segment	3
Impairment and restructuring charges, and acquisition-related costs	$ 21	$ 16
Restructuring charges	18	12
Impairment charges	1	1
Acquisition costs	2	3
Contract and lease termination costs	3
Other restructuring costs	7	5
Series of Individual Business Acquisitions
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Transaction costs	2	3
Employee Severance
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Restructuring charges	4	5
Global Business Center In The Republic Of Philippines
Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]
Restructuring charges	$ 4	$ 2

LONG-TERM DEBT - Schedule of De

LONG-TERM DEBT - Schedule of Debt (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
LONG-TERM DEBT AND LEASE OBLIGATIONS
Finance leases, mortgages and other notes	$ 451	$ 453
Unamortized issue costs and note discounts	(125)	(131)
Total long-term debt	15,083	15,079
Less: Current portion	148	145
Long-term debt, net of current portion	14,935	14,934
Senior Notes | 6.125% due 2028
LONG-TERM DEBT AND LEASE OBLIGATIONS
Carrying amount	$ 2,500	2,500
Stated interest rate, percentage	6.125%
Senior Notes | 6.875% due 2031
LONG-TERM DEBT AND LEASE OBLIGATIONS
Carrying amount	$ 362	362
Stated interest rate, percentage	6.875%
Senior Notes | 4.625% due July 2024
LONG-TERM DEBT AND LEASE OBLIGATIONS
Carrying amount	$ 756	756
Stated interest rate, percentage	4.625%
Senior Notes | 4.625% due September 2024
LONG-TERM DEBT AND LEASE OBLIGATIONS
Carrying amount	$ 589	589
Stated interest rate, percentage	4.625%
Senior Notes | 4.875% due 2026
LONG-TERM DEBT AND LEASE OBLIGATIONS
Carrying amount	$ 2,100	2,100
Stated interest rate, percentage	4.875%
Senior Notes | 5.125% due 2027
LONG-TERM DEBT AND LEASE OBLIGATIONS
Carrying amount	$ 1,500	1,500
Stated interest rate, percentage	5.125%
Senior Notes | 4.625% due 2028
LONG-TERM DEBT AND LEASE OBLIGATIONS
Carrying amount	$ 600	600
Stated interest rate, percentage	4.625%
Senior Notes | 4.250% due 2029
LONG-TERM DEBT AND LEASE OBLIGATIONS
Carrying amount	$ 1,400	1,400
Stated interest rate, percentage	4.25%
Senior Notes | 4.375% due 2030
LONG-TERM DEBT AND LEASE OBLIGATIONS
Carrying amount	$ 1,450	1,450
Stated interest rate, percentage	4.375%
Senior Notes | 6.125% due 2030
LONG-TERM DEBT AND LEASE OBLIGATIONS
Carrying amount	$ 2,000	2,000
Stated interest rate, percentage	6.125%
Senior Notes | 6.250% due 2027
LONG-TERM DEBT AND LEASE OBLIGATIONS
Carrying amount	$ 1,500	$ 1,500
Stated interest rate, percentage	6.25%

LONG-TERM DEBT - Senior Unsecur

LONG-TERM DEBT - Senior Unsecured and Senior Secured Notes (Details) - Senior Notes $ in Millions	Mar. 31, 2023 USD ($)
LONG-TERM DEBT AND LEASE OBLIGATIONS
Long term debt, face amount	$ 14,757
4.250% due 2029
LONG-TERM DEBT AND LEASE OBLIGATIONS
Stated interest rate, percentage	4.25%
6.875% due 2031
LONG-TERM DEBT AND LEASE OBLIGATIONS
Stated interest rate, percentage	6.875%

LONG-TERM DEBT - Narrative (Det

LONG-TERM DEBT - Narrative (Details)	3 Months Ended
	Mar. 31, 2023 USD ($) day	Mar. 31, 2022 USD ($)	Feb. 28, 2022 USD ($)
Credit Agreement
LONG-TERM DEBT AND LEASE OBLIGATIONS
Revolving credit facility, maximum borrowing capacity (up to)			$ 1,900,000,000
Cash borrowings outstanding	$ 0
Standby letters of credit outstanding (less than)	1,000,000
Amount available for borrowing under revolving credit facility	$ 1,500,000,000
Credit Agreement | Minimum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Unused commitment fee (percentage)	0.25%
Credit Agreement | Maximum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Unused commitment fee (percentage)	0.375%
Credit Agreement | Base rate | Minimum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate (percentage)	0.25%
Credit Agreement | Base rate | Maximum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate (percentage)	0.75%
Credit Agreement | Secured Overnight Financing Rate (SOFR) And Euro Interbank Offered Rate (EURIBOR) | Minimum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate (percentage)	1.25%
Credit Agreement | Secured Overnight Financing Rate (SOFR) And Euro Interbank Offered Rate (EURIBOR) | Maximum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate (percentage)	1.75%
Credit Agreement | Secured Overnight Financing Rate (SOFR)
LONG-TERM DEBT AND LEASE OBLIGATIONS
Basis spread on credit spread	0.10%
Credit Agreement | Revolving Credit Facility
LONG-TERM DEBT AND LEASE OBLIGATIONS
Revolving credit facility, maximum borrowing capacity (up to)	$ 1,500,000,000	$ 1,500,000,000
Credit Agreement | Letter of Credit
LONG-TERM DEBT AND LEASE OBLIGATIONS
Line of credit facility, sub facility maximum available capacity	200,000,000
Letter of Credit
LONG-TERM DEBT AND LEASE OBLIGATIONS
Revolving credit facility, maximum borrowing capacity (up to)	200,000,000
Standby letters of credit outstanding (less than)	$ 116,000,000
Secured debt to EBITDA ratio	3
Interest rate on issued but undrawn letters of credit	1.50%
Issuance fee, based on face amount (percentage)	0.125%
Maximum secured debt covenant ratio	4.25
Letter of Credit | Minimum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Unused commitment fee (percentage)	0.25%
Letter of Credit | Maximum
LONG-TERM DEBT AND LEASE OBLIGATIONS
Unused commitment fee (percentage)	0.375%
Number of business days after notice, for reimbursement of amount drawn | day	3
Letter of Credit | Base rate
LONG-TERM DEBT AND LEASE OBLIGATIONS
Margin on variable rate (percentage)	0.50%

GUARANTEES (Details)

GUARANTEES (Details) $ in Millions	Mar. 31, 2023 USD ($)
Income and Revenue Collection Guarantee
GUARANTEES
Maximum potential amount of future payments under guarantees	$ 207
Income and Revenue Collection Guarantee | Other current liabilities
GUARANTEES
Liability for the fair value of guarantees	187
Guaranteed Investees of Third Parties
GUARANTEES
Maximum potential amount of future payments under guarantees	105
Guaranteed Investees of Third Parties | Other current liabilities
GUARANTEES
Guarantee obligations for consolidated subsidiaries	$ 29

EMPLOYEE BENEFIT PLANS - Narrat

EMPLOYEE BENEFIT PLANS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Payment Arrangement [Abstract]
Stock-based compensation costs, pretax	$ 14	$ 16

EMPLOYEE BENEFIT PLANS - Range

EMPLOYEE BENEFIT PLANS - Range of Exercise Prices (Details) - Stock Options - USD ($) $ / shares in Units, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Number of Options
Number of Options Outstanding (in shares)	460,947
Weighted average remaining contractual life (in shares )	4 years 10 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 23.33
Exercised (in shares)	0	60,051
Aggregate Intrinsic value of awards exercised		$ 4
Outstanding at the end of the period	$ 17
$18.99 to $20.609
Number of Options
Number of Options Outstanding (in shares)	293,796
Weighted average remaining contractual life (in shares )	4 years 4 months 24 days
Weighted Average Exercise Price (in dollars per share)	$ 19.75
$18.99 to $20.609
Number of Options
Number of Options Outstanding (in shares)	167,151
Weighted average remaining contractual life (in shares )	5 years 9 months 18 days
Weighted Average Exercise Price (in dollars per share)	$ 29.62
Minimum | $18.99 to $20.609
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price per share, low end of the range (in dollars per share)	18.99
Minimum | $18.99 to $20.609
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price per share, low end of the range (in dollars per share)	20.61
Maximum | $18.99 to $20.609
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price per share, high end of the range (in dollars per share)	20.609
Maximum | $18.99 to $20.609
Share-based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price per share, high end of the range (in dollars per share)	$ 35.430

EMPLOYEE BENEFIT PLANS - Restri

EMPLOYEE BENEFIT PLANS - Restricted Stock Units (Details) $ / shares in Units, $ in Millions	1 Months Ended	3 Months Ended
	Oct. 31, 2022 shares	Mar. 31, 2023 USD ($) $ / shares shares	Mar. 31, 2022 quarter shares
Restricted Stock Units
Number of RSUs
Unvested at the beginning of the period (in shares)		1,520,418
Granted (in shares)		678,748	570,080
Vested (in shares)		(823,418)
Forfeited (in shares)		(26,660)
Unvested at the end of the period (in shares)		1,534,989
Weighted Average Grant Date Fair Value Per RSU
Unvested at the beginning of the period (in dollars per share) | $ / shares		$ 66.36
Granted (in dollars per share) | $ / shares		62.45
Vested (in dollars per share) | $ / shares		52.95
Forfeited (in dollars per share) | $ / shares		56.31
Unvested at the end of the period (in dollars per share) | $ / shares		$ 65.58
Other Disclosures
Awards granted in the period (in shares)		678,748	570,080
Unrecognized compensation costs | $		$ 63
Period for recognition of unrecognized compensation costs		2 years 2 months 12 days
Restricted Stock Units | Time Based Vesting, Three Year Period from Grant Date
Number of RSUs
Granted (in shares)		301,268	228,239
Other Disclosures
Awards granted in the period (in shares)		301,268	228,239
Vesting period		3 years	3 years
Restricted Stock Units | Time Based Vesting, Settled on Fifth Anniversary
Number of RSUs
Granted (in shares)		42,626
Other Disclosures
Awards granted in the period (in shares)		42,626
Restricted Stock Units | Time Based Vesting, Settled on December 31 2023
Number of RSUs
Granted (in shares)		33,586
Other Disclosures
Awards granted in the period (in shares)		33,586
Restricted Stock Units | Eleven Quarter Vesting Period
Other Disclosures
Award vesting period, number of quarterly periods | quarter			11
Restricted Stock Units | Time Based Vesting, Evenly On The Third And Fourth Anniversary
Number of RSUs
Granted (in shares)			6,170
Other Disclosures
Awards granted in the period (in shares)			6,170
Performance Based Restricted Stock Unit
Number of RSUs
Granted (in shares)		185,901	53,716
Vested (in shares)	(53,716)
Weighted Average Grant Date Fair Value Per RSU
Granted (in dollars per share) | $ / shares		$ 48.97
Other Disclosures
Awards granted in the period (in shares)		185,901	53,716
Vesting percentage			100%
Performance Based Restricted Stock Unit | Minimum
Other Disclosures
Vesting percentage			0%
Performance Based Restricted Stock Unit | Maximum
Other Disclosures
Vesting percentage			200%
Performance Based Restricted Stock Unit | Performance based vesting on the third anniversary
Number of RSUs
Granted (in shares)		301,268	281,955
Other Disclosures
Awards granted in the period (in shares)		301,268	281,955
Performance Based Restricted Stock Unit | Performance Based Vesting And Settled Immediately
Number of RSUs
Granted (in shares)		185,901
Other Disclosures
Awards granted in the period (in shares)		185,901
Performance Based Restricted Stock Unit | Performance Based Vesting | Minimum
Other Disclosures
Vesting percentage		0%
Performance Based Restricted Stock Unit | Performance Based Vesting | Maximum
Other Disclosures
Vesting percentage		225%
Restricted Stock Units, Including Performance Based Adjustment
Number of RSUs
Granted (in shares)		864,649
Other Disclosures
Awards granted in the period (in shares)		864,649
Time Based Restricted Stock Untis | Eleven Quarter Vesting Period
Number of RSUs
Granted (in shares)			53,716
Vested (in shares)	(53,716)
Other Disclosures
Awards granted in the period (in shares)			53,716

EMPLOYEE BENEFIT PLANS - Valuat

EMPLOYEE BENEFIT PLANS - Valuation of Restricted Stock Units (Details) - Restricted Stock Units	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	53.60%	39.60%
Risk-free interest rate	4.50%	1%
Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	65.60%	68.10%
Risk-free interest rate	4.80%	1.70%

EMPLOYEE BENEFIT PLANS - USPI M

EMPLOYEE BENEFIT PLANS - USPI Management Equity Plan (Details) - USPI Management Equity Plan - $ / shares	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Number of RSUs
Unvested at the beginning of the period (in shares)	922,840
Vested (in shares)	(303,171)
Unvested at the end of the period (in shares)	619,669
Weighted Average Grant Date Fair Value Per RSU
Unvested at the beginning of the period (in dollars per share)	$ 34.13
Vested (in dollars per share)	34.13
Unvested at the end of the period (in dollars per share)	$ 34.13
Noncontrolling interest purchased during period through issuance of equity (in shares)	0	0
Restricted Non-Voting Common Stock
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Contractual right to receive shares of common stock for a stock based award (in shares)	1
Nonvoting Common Stock
Weighted Average Grant Date Fair Value Per RSU
Outstanding vested shares eligible to be sold (in shares)	308,495

EQUITY - Changes in Shareholder

EQUITY - Changes in Shareholders' Equity (Details) - USD ($) shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Changes in Shareholders' Equity
Balances, beginning of period	$ 2,459	$ 2,054
Net income	217	186
Distributions paid to noncontrolling interests	(61)	(71)
Other comprehensive income	2	0
Accretion of redeemable noncontrolling interests		(95)
Purchases (sales) of businesses and noncontrolling interests, net	19	(8)
Repurchases of common stock	(50)
Stock-based compensation expense and issuance of common stock	(6)	(10)
Balances, end of period	$ 2,580	$ 2,056
Common Stock
Changes in Shareholders' Equity
Balances, beginning of period (in shares)	102,247	107,189
Balances, beginning of period	$ 8	$ 8
Repurchases of common stock (in shares)	(906)
Stock-based compensation expense and issuance of common stock (in shares)	571	499
Balances, end of period (in shares)	101,912	107,688
Balances, end of period	$ 8	$ 8
Additional Paid-In Capital
Changes in Shareholders' Equity
Balances, beginning of period	4,778	4,877
Accretion of redeemable noncontrolling interests		(95)
Purchases (sales) of businesses and noncontrolling interests, net	2	(7)
Stock-based compensation expense and issuance of common stock	(6)	(10)
Balances, end of period	4,774	4,765
Accumulated Other Comprehensive Loss
Changes in Shareholders' Equity
Balances, beginning of period	(181)	(233)
Other comprehensive income	2
Balances, end of period	(179)	(233)
Accumulated Deficit
Changes in Shareholders' Equity
Balances, beginning of period	(803)	(1,214)
Net income	143	140
Balances, end of period	(660)	(1,074)
Treasury Stock
Changes in Shareholders' Equity
Balances, beginning of period	(2,660)	(2,410)
Repurchases of common stock	(50)
Balances, end of period	(2,710)	(2,410)
Noncontrolling Interests
Changes in Shareholders' Equity
Balances, beginning of period	1,317	1,026
Net income	74	46
Distributions paid to noncontrolling interests	(61)	(71)
Purchases (sales) of businesses and noncontrolling interests, net	17	(1)
Balances, end of period	$ 1,347	$ 1,000

EQUITY - Narrative (Details)

EQUITY - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022	Oct. 31, 2022	Dec. 31, 2021
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders equity balance	$ 2,580	$ 2,056	$ 2,459		$ 2,054
Net income	217	186
Amount of common stock authorized to be repurchased				$ 1,000
Noncontrolling Interests
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders equity balance	1,347	1,000	1,317		$ 1,026
Net income	74	46
Noncontrolling Interests | Hospital Operations
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders equity balance	131		132
Net income	5	3
Noncontrolling Interests | Ambulatory Care
Accumulated Other Comprehensive Income (Loss) [Line Items]
Stockholders equity balance	1,216		$ 1,185
Net income	$ 69	$ 43

EQUITY - Share Repurchase Progr

EQUITY - Share Repurchase Programs (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	1 Months Ended
	Mar. 31, 2023	Feb. 28, 2023	Jan. 31, 2023
Equity [Abstract]
Total Number of Shares Purchased (in shares)	906	0	0
Average Price Paid per Share (in dollars per shares)	$ 55.03	$ 0	$ 0
Maximum Dollar Value of Shares That May Yet be Purchased Under the Program	$ 700	$ 750	$ 750

NET OPERATING REVENUES - Net Op

NET OPERATING REVENUES - Net Operating Revenue By Source (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Net operating revenues	$ 5,021	$ 4,745
Reimbursement program assessments	26	57
Ambulatory Care
Disaggregation of Revenue [Line Items]
Net operating revenues	905	738
Conifer
Disaggregation of Revenue [Line Items]
Net operating revenues	324	324
Operating Segments | Ambulatory Care
Disaggregation of Revenue [Line Items]
Net operating revenues	905	738
Operating Segments | Conifer
Disaggregation of Revenue [Line Items]
Net operating revenues	324	324
Inter-segment eliminations
Disaggregation of Revenue [Line Items]
Net operating revenues	(107)	(115)
Continuing operations:
Disaggregation of Revenue [Line Items]
Net operating revenues	5,021	4,745
Continuing operations: | Operating Segments | Hospital Operations
Disaggregation of Revenue [Line Items]
Net operating revenues	3,899	3,798
Continuing operations: | Operating Segments | Hospital Operations | Other Revenues
Disaggregation of Revenue [Line Items]
Net operating revenues	332	290
Continuing operations: | Operating Segments | Ambulatory Care
Disaggregation of Revenue [Line Items]
Net operating revenues	905	738
Continuing operations: | Operating Segments | Conifer
Disaggregation of Revenue [Line Items]
Net operating revenues	324	324
Continuing operations: | Inter-segment eliminations
Disaggregation of Revenue [Line Items]
Net operating revenues	(107)	(115)
Continuing operations: | Acute Care Hospitals and Related Outpatient Facilities | Operating Segments | Hospital Operations | Medicare
Disaggregation of Revenue [Line Items]
Net operating revenues	613	619
Continuing operations: | Acute Care Hospitals and Related Outpatient Facilities | Operating Segments | Hospital Operations | Medicaid
Disaggregation of Revenue [Line Items]
Net operating revenues	280	249
Continuing operations: | Acute Care Hospitals and Related Outpatient Facilities | Operating Segments | Hospital Operations | Managed care
Disaggregation of Revenue [Line Items]
Net operating revenues	2,503	2,438
Continuing operations: | Acute Care Hospitals and Related Outpatient Facilities | Operating Segments | Hospital Operations | Uninsured
Disaggregation of Revenue [Line Items]
Net operating revenues	31	38
Continuing operations: | Acute Care Hospitals and Related Outpatient Facilities | Operating Segments | Hospital Operations | Indemnity and other
Disaggregation of Revenue [Line Items]
Net operating revenues	140	164
Continuing operations: | Acute Care Hospitals and Related Outpatient Facilities | Operating Segments | Hospital Operations | Total
Disaggregation of Revenue [Line Items]
Net operating revenues	$ 3,567	$ 3,508

NET OPERATING REVENUES - Net _2

NET OPERATING REVENUES - Net Operating Revenue Composition, Ambulatory and Conifer Segments (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Disaggregation of Revenue [Line Items]
Net operating revenues	$ 5,021	$ 4,745
Ambulatory Care
Disaggregation of Revenue [Line Items]
Net operating revenues	905	738
Ambulatory Care | Net patient service revenues
Disaggregation of Revenue [Line Items]
Net operating revenues	868	704
Ambulatory Care | Management fees
Disaggregation of Revenue [Line Items]
Net operating revenues	30	29
Ambulatory Care | Revenue from other sources
Disaggregation of Revenue [Line Items]
Net operating revenues	7	5
Conifer
Disaggregation of Revenue [Line Items]
Net operating revenues	324	324
Conifer | Revenue Cycle Services | Tenet
Disaggregation of Revenue [Line Items]
Net operating revenues	104	112
Conifer | Revenue Cycle Services | Other Customers
Disaggregation of Revenue [Line Items]
Net operating revenues	199	189
Conifer | Other Services | Tenet
Disaggregation of Revenue [Line Items]
Net operating revenues	3	3
Conifer | Other Services | Other Customers
Disaggregation of Revenue [Line Items]
Net operating revenues	$ 18	$ 20

NET OPERATING REVENUES - Perfor

NET OPERATING REVENUES - Performance Obligations (Details) - Conifer $ in Millions	Mar. 31, 2023 USD ($)
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations	$ 5,926
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2023-04-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations	$ 500
Revenue, remaining performance obligation, expected timing of satisfaction, period	9 months
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2024-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations	$ 603
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations	$ 603
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations	$ 603
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations	$ 603
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Performance obligations	$ 3,014
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

INSURANCE - Insurance (Details)

INSURANCE - Insurance (Details) - USD ($) $ in Millions	3 Months Ended		24 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2024	Dec. 31, 2022
Insurance coverage
Insurance recoveries	$ 31
Net operating revenues	5,021	$ 4,745
Scenario, Forecast
Insurance coverage
Insurance, annual coverage limit			$ 850
Insurance Recoveries
Insurance coverage
Net operating revenues	27
Other Operating Expense, Net
Insurance coverage
Malpractice expense	91	$ 81
Professional and General Liability Reserves
Insurance coverage
Self insurance reserve	$ 1,066			$ 1,045
Floods | Scenario, Forecast
Insurance coverage
Insurance, maximum coverage per incident			100
Earthquake | California | Scenario, Forecast
Insurance coverage
Insurance, maximum coverage per incident			200
Earthquake | Other Geographic Areas | Scenario, Forecast
Insurance coverage
Insurance, maximum coverage per incident			200
Windstorms | Scenario, Forecast
Insurance coverage
Insurance, maximum coverage per incident			200
Fire and other perils | Scenario, Forecast
Insurance coverage
Insurance, maximum coverage per incident			$ 850
California Earthquakes And Named Windstorms | Scenario, Forecast
Insurance coverage
Insurance deductible as a percent			5%
New Madrid Fault Earthquakes | Scenario, Forecast
Insurance coverage
Insurance deductible as a percent			2%
Insurance, maximum deductible per incident			$ 25
Other Catastrophic Events | Scenario, Forecast
Insurance coverage
Insurance, deductible			$ 5

CLAIMS AND LAWSUITS - Reconcili

CLAIMS AND LAWSUITS - Reconciliations (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Loss Contingency Accrual [Roll Forward]
Litigation and investigation costs	$ 4	$ 20
Claims, Lawsuits, and Regulatory Proceedings
Loss Contingency Accrual [Roll Forward]
Litigation reserve, balance at beginning of period	51	78
Litigation and investigation costs	4	20
Cash Payments	(5)	(36)
Other	0	2
Litigation reserve, balance at end of period	$ 50	$ 64

REDEEMABLE NONCONTROLLING INT_3

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Narrative (Details) - USD ($) $ in Millions	1 Months Ended	3 Months Ended
	Jun. 30, 2022	Mar. 31, 2023	Dec. 31, 2022
Redeemable Noncontrolling Interest [Line Items]
Other current liabilities		$ 1,674	$ 1,471
Other long-term liabilities		1,748	$ 1,800
United Surgical Partners International
Redeemable Noncontrolling Interest [Line Items]
Purchases and sales of businesses and noncontrolling interests, net	$ 365
Loss from purchase of noncontrolling interests	$ 23
Other current liabilities		135
Other long-term liabilities		159
Baylor University Medical Center
Redeemable Noncontrolling Interest [Line Items]
Duration of monthly payments	35 months
Baylor University Medical Center | United Surgical Partners International
Redeemable Noncontrolling Interest [Line Items]
Share purchase agreement amount of payment	$ 406
Share purchase agreement, payment for execution	$ 11
Payment on execution of Share Purchase Agreement		$ 11
Baylor University Medical Center | Put Option | United Surgical Partners International
Redeemable Noncontrolling Interest [Line Items]
Ownership percentage	5%

REDEEMABLE NONCONTROLLING INT_4

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Changes in Redeemable Noncontrolling Interests (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Increase (Decrease) in Temporary Equity [Roll Forward]
Balances at beginning of period	$ 2,149
Net income	79	$ 94
Distributions paid to noncontrolling interests	(61)	(71)
Balances at end of period	2,225
Redeemable Noncontrolling Interests
Increase (Decrease) in Temporary Equity [Roll Forward]
Balances at beginning of period	2,149	2,203
Net income	79	94
Distributions paid to noncontrolling interests	(73)	(64)
Accretion of redeemable noncontrolling interests	0	95
Purchases and sales of businesses and noncontrolling interests, net	70	30
Balances at end of period	$ 2,225	$ 2,358

REDEEMABLE NONCONTROLLING INT_5

REDEEMABLE NONCONTROLLING INTERESTS IN EQUITY OF CONSOLIDATED SUBSIDIARIES - Segment Details (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Redeemable Noncontrolling Interest [Line Items]
Redeemable noncontrolling interests	$ 2,225		$ 2,149
Net income available to redeemable noncontrolling interests	79	$ 94
Hospital Operations
Redeemable Noncontrolling Interest [Line Items]
Redeemable noncontrolling interests	230		233
Net income available to redeemable noncontrolling interests	0	22
Ambulatory Care
Redeemable Noncontrolling Interest [Line Items]
Redeemable noncontrolling interests	1,414		1,357
Net income available to redeemable noncontrolling interests	57	56
Conifer
Redeemable Noncontrolling Interest [Line Items]
Redeemable noncontrolling interests	581		$ 559
Net income available to redeemable noncontrolling interests	$ 22	$ 16

INCOME TAXES - Narrative (Detai

INCOME TAXES - Narrative (Details) - USD ($)	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Taxes
Income tax expense	$ 84,000,000	$ 99,000,000
Income from continuing operations, before income taxes	380,000,000	378,000,000
Change in valuation allowance for interest expense carryforwards	19,000,000	32,000,000
Unrecognized tax benefits	34,000,000
Unrecognized tax benefits which, if recognized, would impact effective tax rate	32,000,000
Interest and penalties related to accrued liabilities for uncertain tax positions, recognized	0
Interest and penalties related to accrued liabilities for uncertain tax positions, recognized	1,000,000
Continuing operations:
Income Taxes
Income tax expense	$ 84,000,000	$ 99,000,000

INCOME TAXES - Federal Tax Reco

INCOME TAXES - Federal Tax Reconciliation (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Reconciliation between reported income tax expense (benefit) and income taxes calculated by the statutory federal income tax rate
Tax expense at statutory federal rate of 21%	$ 80	$ 79
State income taxes, net of federal income tax benefit	16	14
Tax benefit attributable to noncontrolling interests	(32)	(29)
Stock-based compensation tax benefit	(2)	(2)
Changes in valuation allowance	19	32
Other items	3	5
Income tax expense	$ 84	$ 99

EARNINGS PER COMMON SHARE (Deta

EARNINGS PER COMMON SHARE (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Net Income Available to Common Shareholders (Numerator)
Net income attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share	$ 143	$ 139
Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock	(3)	3
Net income available to Tenet Healthcare Corporation common shareholders for diluted earnings per share	$ 140	$ 142
Weighted Average Shares (Denominator)
Net income attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share (in shares)	102,289	107,483
Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock (in shares)	3,717	4,537
Net income attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share (in shares)	106,006	112,020
Per-Share Amount
Net income attributable to Tenet Healthcare Corporation common shareholders for basic earnings per share (in dollars per share)	$ 1.40	$ 1.29
Effect of dilutive stock options, restricted stock units, deferred compensation units, convertible instruments and dividends on preferred stock (in dollars per share)	(0.08)	(0.02)
Net income attributable to Tenet Healthcare Corporation common shareholders for diluted earnings per share (in dollars per share)	$ 1.32	$ 1.27

FAIR VALUE MEASUREMENTS (Detail

FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Millions	Mar. 31, 2023	Dec. 31, 2022
Nonrecurring
Fair value of assets and liabilities measured on recurring basis
Long-lived assets held for sale	$ 142
Long-lived assets held and used		$ 167
Nonrecurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair value of assets and liabilities measured on recurring basis
Long-lived assets held for sale	0
Long-lived assets held and used		0
Nonrecurring | Significant Other Observable Inputs (Level 2)
Fair value of assets and liabilities measured on recurring basis
Long-lived assets held for sale	142
Long-lived assets held and used		167
Nonrecurring | Significant Unobservable Inputs (Level 3)
Fair value of assets and liabilities measured on recurring basis
Long-lived assets held for sale	$ 0
Long-lived assets held and used		$ 0
Recurring | Quoted Prices in Active Markets for Identical Assets (Level 1)
Fair value of assets and liabilities measured on recurring basis
Estimated fair value of debt instrument as percentage of carrying value (percent)	95.80%	92.80%

ACQUISITIONS - Preliminary Purc

ACQUISITIONS - Preliminary Purchase Price Allocations (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Final purchase price allocations
Goodwill	$ 10,258		$ 10,123
Cash paid, net of cash acquired	(48)	$ (40)
Gains on consolidations	13	0
Series of Individual Business Acquisitions
Final purchase price allocations
Current assets	6	3
Property and equipment	4	10
Other intangible assets	2	2
Goodwill	165	84
Other long-term assets	4	11
Previously held investments in unconsolidated affiliates	(37)	(18)
Current liabilities	(5)	(5)
Long-term liabilities	(8)	(19)
Redeemable noncontrolling interests in equity of consolidated subsidiaries	(56)	(28)
Noncontrolling interests	(14)	0
Cash paid, net of cash acquired	$ (48)	$ (40)

ACQUISITIONS - Narrative (Detai

ACQUISITIONS - Narrative (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Business Acquisition [Line Items]
Goodwill	$ 10,258		$ 10,123
Goodwill, purchase accounting adjustments	1
SurgeCenter Development
Business Acquisition [Line Items]
Goodwill	165	$ 84
Transaction costs related to prospective and closed acquisitions	$ 2	$ 3

SEGMENT INFORMATION - General I

SEGMENT INFORMATION - General Information and Customer Concentration (Details) $ in Millions	1 Months Ended	3 Months Ended
	Jun. 30, 2022 USD ($)	Mar. 31, 2023 hospital state surgery_center	Jun. 29, 2022
Conifer Health Solutions, LLC
Segment Reporting Information [Line Items]
Ownership percentage by parent (percent)		76%
Baylor University Medical Center | United Surgical Partners International
Segment Reporting Information [Line Items]
Share purchase agreement amount of payment | $	$ 406
Hospital Operations
Segment Reporting Information [Line Items]
Number of hospitals operated by subsidiaries		61
Number of states where operations occur | state		9
Ambulatory Care | United Surgical Partners International
Segment Reporting Information [Line Items]
Ownership percentage by parent (percent)	100%		95%
Ambulatory Care | United Surgical Partners International
Segment Reporting Information [Line Items]
Number of states where operations occur | state		35
Number of ambulatory surgery centers operated by subsidiaries | surgery_center		445
Number of ambulatory surgery centers consolidated | surgery_center		305
Number of surgical hospitals operated by subsidiaries		24
Number of surgical hospitals consolidated		8
Conifer | Minimum
Segment Reporting Information [Line Items]
Number of hospitals to which segment of the entity provides revenue cycle services		665

SEGMENT INFORMATION - Reconcili

SEGMENT INFORMATION - Reconciling Items (Details) - USD ($) $ in Millions	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Segment Reporting Information [Line Items]
Assets	$ 27,067		$ 27,156
Capital expenditures:	235	$ 155
Net operating revenues	5,021	4,745
Equity in earnings of unconsolidated affiliates:	50	46
Adjusted Segment EBITDA [Abstract]
Adjusted EBITDA:	832	888
Depreciation and amortization	217	203
Depreciation and amortization:	(217)	(203)
Impairment and restructuring charges, and acquisition-related costs	(21)	(16)
Litigation and investigation costs	(4)	(20)
Interest expense	(221)	(227)
Loss from early extinguishment of debt	0	(43)
Other non-operating expense, net	(2)	0
Net gains (losses) on sales, consolidation and deconsolidation of facilities	13	(1)
Income from continuing operations, before income taxes	380	378
Inter-segment eliminations
Segment Reporting Information [Line Items]
Net operating revenues	(107)	(115)
Hospital Operations
Segment Reporting Information [Line Items]
Assets	15,397		15,682
Capital expenditures:	215	132
Equity in earnings of unconsolidated affiliates:	3	4
Adjusted Segment EBITDA [Abstract]
Adjusted EBITDA:	405	514
Depreciation and amortization	181	167
Depreciation and amortization:	(181)	(167)
Hospital Operations | Operating Segments
Segment Reporting Information [Line Items]
Net operating revenues	3,899	3,798
Ambulatory Care
Segment Reporting Information [Line Items]
Assets	10,733		10,557
Capital expenditures:	18	21
Net operating revenues	905	738
Equity in earnings of unconsolidated affiliates:	47	42
Adjusted Segment EBITDA [Abstract]
Adjusted EBITDA:	340	282
Depreciation and amortization	27	27
Depreciation and amortization:	(27)	(27)
Ambulatory Care | Operating Segments
Segment Reporting Information [Line Items]
Net operating revenues	905	738
Conifer
Segment Reporting Information [Line Items]
Assets	937		$ 917
Capital expenditures:	2	2
Net operating revenues	324	324
Adjusted Segment EBITDA [Abstract]
Adjusted EBITDA:	87	92
Depreciation and amortization	9	9
Depreciation and amortization:	(9)	(9)
Conifer | Operating Segments
Segment Reporting Information [Line Items]
Net operating revenues	324	324
Conifer | Tenet | Operating Segments
Segment Reporting Information [Line Items]
Net operating revenues	107	115
Conifer | Other Customers | Operating Segments
Segment Reporting Information [Line Items]
Net operating revenues	$ 217	$ 209